CHIR-99021 (CT99021) HCl

Name: CHIR-99021 (CT99021) HCl
Brand: Selleck Chemicals
SKU: S2924
Rating: 5 (134 reviews)

For research use only.

Catalog No.S2924

134 publications

CHIR-99021 (CT99021) HCl Chemical Structure

Molecular Weight(MW): 501.8

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.

Selleck's CHIR-99021 (CT99021) HCl has been cited by 134 publications

Cell Stem Cell, 2019, 24(5):802-811

PubMed: 30880024 ( click the link to review the publication )

Cell, 2018, 174(2):406-421

PubMed: 29887375 ( click the link to review the publication )

Cell, 2018, 174(2):391-405

PubMed: 29937225 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):462-477

PubMed: 28111200 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(5):720-731

PubMed: 28343982 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):518-532

PubMed: 28017796 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14413

PubMed: 25945737 ( click the link to review the publication )

Cell Stem Cell, 2015, 10.1016/j.stem.2015.04.020

PubMed: ( click the link to review the publication )

Nat Biotechnol, 2014, 32(11):1121-33

PubMed: 25211370 ( click the link to review the publication )

Nature, 2013, 500(7461):222-6

PubMed: 23812591 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa067

PubMed: 32016422 ( click the link to review the publication )

EBioMedicine, 2020, 53:102695

PubMed: 32143182 ( click the link to review the publication )

Cell Host Microbe, 2020, 27(1):41-53

PubMed: 31862381 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):100

PubMed: 32127035 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(9):1152-1163

PubMed: 31481791 ( click the link to review the publication )

Blood, 2019, blood.2019001037

PubMed: 31570489 ( click the link to review the publication )

Nat Commun, 2019, 10(1):928

PubMed: 30804331 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2939

PubMed: 31270324 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3477

PubMed: 31375664 ( click the link to review the publication )

Sci Adv, 2019, 5(11):eaax7525

PubMed: 31807705 ( click the link to review the publication )

Dev Cell, 2019, 50(2):212-228.e6

PubMed: 31178404 ( click the link to review the publication )

Cell Syst, 2019, 8(5):427-445

PubMed: 31078527 ( click the link to review the publication )

Cell Syst, 2019, 8(5):427-445

PubMed: 31078527 ( click the link to review the publication )
Cell Rep, 2019, 26(13):3643-3656

PubMed: 30917318 ( click the link to review the publication )

Cell Rep, 2019, 29(8):2461-2472

PubMed: 31747613 ( click the link to review the publication )

Int J Cancer, 2019, 144(2):389-401

PubMed: 29978469 ( click the link to review the publication )

Oncogene, 2019, 38(15):2788-2799

PubMed: 30542117 ( click the link to review the publication )

Mol Metab, 2019, 24:80-97

PubMed: 30930126 ( click the link to review the publication )

PLoS Pathog, 2019, 15(3):e1007667

PubMed: 30901352 ( click the link to review the publication )

FASEB J, 2019, 33(2):2694-2706

PubMed: 30307767 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0605

PubMed: 31395667 ( click the link to review the publication )

Front Neurosci, 2019, 13:867

PubMed: 31551670 ( click the link to review the publication )

Front Physiol, 2019, 10:818

PubMed: 31316396 ( click the link to review the publication )

Cell Cycle, 2019, 18(19):2495-2508

PubMed: 31411525 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):5440-5452

PubMed: 31059099 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5230

PubMed: 30531796 ( click the link to review the publication )

Sci Adv, 2018, 4(5):eaat0351

PubMed: 29795786 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Cell Rep, 2018, 25(7):1966-1981.e4

PubMed: 30428361 ( click the link to review the publication )

Cell Rep, 2018, 25(9):2563-2576

PubMed: 30485820 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Stem Cell Reports, 2018, 11(2):497-513

PubMed: 30033084 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):22

PubMed: 29426364 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):598

PubMed: 29789524 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(9):1095-1106

PubMed: 30251630 ( click the link to review the publication )
Dig Dis Sci, 2018, 63(10):2604-2616

PubMed: 29948558 ( click the link to review the publication )

Biol Open, 2018, 7(9)

PubMed: 30135081 ( click the link to review the publication )

Methods Mol Biol, 2018, 1649:473-488

PubMed: 29130217 ( click the link to review the publication )

Curr Protoc Hum Genet, 2018, 10.1002/cphg.64

PubMed: 29979824 ( click the link to review the publication )

Methods Mol Biol, 2018, 1733:127-136

PubMed: 29435928 ( click the link to review the publication )

Cell Res, 2017, 27(6):815-829

PubMed: 28429771 ( click the link to review the publication )

Mol Cell, 2017, 66(4):568-576

PubMed: 28483418 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(31):25929-25940

PubMed: 28718622 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3107

PubMed: 29022923 ( click the link to review the publication )

Biomater Sci, 2017, 5(8):1567-1578

PubMed: 28715029 ( click the link to review the publication )

Stem Cell Res Ther, 2017, 8(1):156

PubMed: 28676082 ( click the link to review the publication )

Sci Rep, 2017, 7(1):9490

PubMed: 28842634 ( click the link to review the publication )

Biofabrication, 2017, 9(2):025007

PubMed: 28287080 ( click the link to review the publication )

JCI Insight, 2017, 2(18)

PubMed: 28931764 ( click the link to review the publication )

Stem Cells, 2016, 34(7):1765-75

PubMed: 26946228 ( click the link to review the publication )

Sci Rep, 2016, 6:23817

PubMed: 27026509 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0161508

PubMed: 27560518 ( click the link to review the publication )

Exp Ther Med, 2016, 12(6):3851-3858

PubMed: 28101169 ( click the link to review the publication )

Methods Mol Biol, 2016, 1353:181-90

PubMed: 25523811 ( click the link to review the publication )

Methods Mol Biol, 2016, 1480:153-65

PubMed: 27659983 ( click the link to review the publication )

Stem Cell Reports, 2016, 7(5):884-896

PubMed: 27720906 ( click the link to review the publication )

Nat Commun, 2015, 6:7413

PubMed: 26172574 ( click the link to review the publication )

Dev Cell, 2015, 32(6):667-77

PubMed: 25805134 ( click the link to review the publication )

Stem Cell Res, 2015, 10.1016/j.scr.2015.05.004

PubMed: ( click the link to review the publication )
Stem Cells, 2015, 33(3):686-98

PubMed: ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Mol Neurobiol, 2015, 10.1007/s12035-014-9084-z

PubMed: 25663198 ( click the link to review the publication )

J Thromb Haemost, 2015, 10.1111/jth.12954

PubMed: 25858425 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Stem Cells Dev, 2015, 10.1089/scd.2014.0422

PubMed: 25751301 ( click the link to review the publication )

Cell Transplant, 2015, 10.3727/096368914X685762

PubMed: 25562386 ( click the link to review the publication )

Biol Open, 2015, 4(1):48-61

PubMed: ( click the link to review the publication )

J Physiol, 2015, 593(5):1147-57

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144572

PubMed: 26695765 ( click the link to review the publication )

Sci Rep, 2015, 5:9718

PubMed: 25864432 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(6):1128-1142

PubMed: 26626177 ( click the link to review the publication )

Methods Mol Biol, 2015, 10.1007/7651_2015_220

PubMed: 25762297 ( click the link to review the publication )

Methods Mol Biol, 2015, 1264:453-63

PubMed: 25631034 ( click the link to review the publication )

Cell Biology International Reports, 2015, 10.1002/cbi3.10019

PubMed: ( click the link to review the publication )

Circ Res, 2014, 115(6):556-66

PubMed: 25015077 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(12):4484-9

PubMed: 24623855 ( click the link to review the publication )

Biomaterials, 2014, 35(5):1367-77

PubMed: 24268663 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(4):594-605

PubMed: 25358788 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Acta Biomater, 2014, 10(2):604-12

PubMed: 24200714 ( click the link to review the publication )

Protein Cell, 2014, 5(1):59-68

PubMed: 24474197 ( click the link to review the publication )
Mol Cancer Ther, 2014, 13(4):812-22

PubMed: 24552772 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(4):990-1007

PubMed: 24482122 ( click the link to review the publication )

J Biol Chem, 2014, 289(47):32628-38

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 10.1074/jbc.M114.580076

PubMed: 25301940 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14341-50

PubMed: 24692544 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):724-735

PubMed: ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Stem Cells Dev, 2014, 10.1089/scd.2014.0011

PubMed: 24805295 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )

Exp Cell Res, 2014, 328(2):351-60

PubMed: 25172557 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115854

PubMed: 25541965 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85089

PubMed: 24465482 ( click the link to review the publication )

PLoS One, 2014, 9(4):e92304

PubMed: 24743237 ( click the link to review the publication )

Exp Biol Med, 2014, 239(10):1390-402

PubMed: 24951472 ( click the link to review the publication )

Theriogenology, 2014, 82(2):283-93

PubMed: 24853281 ( click the link to review the publication )

Cell Reprogram, 2014, 10.1089/cell.2014.0028

PubMed: 25084370 ( click the link to review the publication )

J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2):151-6

PubMed: 24710923 ( click the link to review the publication )

University of GOTHENBURG, 2014, 5495

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:6425

PubMed: 25236849 ( click the link to review the publication )

Methods Mol Biol, 2014, 10.1007/7651_2014_172

PubMed: 25520292 ( click the link to review the publication )

Nat Commun, 2013, 4:2628

PubMed: 24165455 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(52):E5039-48

PubMed: 24248365 ( click the link to review the publication )

Stem Cell Res, 2013, 12(2):364-375

PubMed: 24365601 ( click the link to review the publication )
Stem Cell Rep, 2013, 1(4):360-10

PubMed: 24319670 ( click the link to review the publication )

Antioxid Redox Sign, 2013, 20(18):2907-22

PubMed: 24219064 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):454-67

PubMed: 24282277 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(8):4102-16

PubMed: 23628704 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35500-10

PubMed: 24165128 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1329-40

PubMed: 23867056 ( click the link to review the publication )

Nat Protoc, 2012, 8(1):162-75

PubMed: 23257984 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(27):E1848-57

PubMed: 22645348 ( click the link to review the publication )

Stem Cells, 2012, 30(9):1863-74

PubMed: 22761013 ( click the link to review the publication )

Carcinogenesis, 2012, 33(3):529-37

PubMed: 22201186 ( click the link to review the publication )

J Biol Chem, 2012, 287(2):893-904

PubMed: 22102280 ( click the link to review the publication )

PLoS One, 2012, 7(10):e47312

PubMed: 23077590 ( click the link to review the publication )

BMC Dev Biol, 2012, 12:21

PubMed: 22846383 ( click the link to review the publication )

Bachelor of Science, 2012, East China Normal University

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description

Targets

GSK-3β ^[1] (Cell-free assay)	GSK-3α ^[1] (Cell-free assay)
6.7 nM	10 nM

In vitro

CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM. ^[1] In addition to simulating the actions of insulin, inhibition of GSK-3 by CHIR-99021 (3 μM) increases free cytosolic β-catenin by 1.9-fold, mimicking the canonical Wnt signaling pathway in 3T3-L1 preadipocytes. During any of the first 3 days of differentiation, CHIR-99021 treatment inhibits the preadipocyte differentiation with IC50 of 0.3 μM by blocking induction of CCAAT/enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ). ^[2] Unlike lithium chloride and AR-A014418, CHIR-99021 treatment does not reduce the viability of INS-1E cells even at high concentrations. Instead, CHIR-99021 robustly increases the rate of proliferation of INS-1E cells in a dose-dependent manner, and significantly inhibits INS-E cell death induced by high glucose and high palmitate in a concentration-dependent manner. CHIR-99021 promotes primary beta cell replication in isolated rat islets at concentrations as low as 1 μM, with 2-3 fold increase of cell replication at 5 μM of CHIR-99021 treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
3T3-L1	M4DVbGZ2dmO2aX;uJGF{e2G7	MmmzN{DPxE1?	MUS0JIg>	MnnkSG1UVw>?	M1rLeWlvcGmkaYTzJJBz\WGmaYDvZ5l1\SCmaX\m[ZJmdnSrYYTpc44>	M4TqSFEzODV3MkCw
insulin receptor–expressing CHO-IR	MXnGeY5kfGmxbjDBd5NigQ>?	NIr2NIo2ODBibl2=	MWGzNEBucW5?	NXXaVIFHTE2VTx?=	NVmzfIc5SWO2aY\heIV{KEeueXPv[4VvKFO7boToZZNmKCiJUzm=	NHLGdmgyOjZyNkS5Oy=>
H4IIE	Mk\ySpVv[3Srb36gRZN{[Xl?	NE\ibpMyOCEQvF2=	MViyOEBp	NH7q[I9FVVOR	NGP3THFT\We3bHH0[ZMh\|rJvY3H0[Y5qdiCjY4Tpeol1gSCjbnSgWGlTTSClb370ZYlvcW6pIIDyc41wfGW{IHHjeIl3cXS7	MYqxOVM2ODF7NR?=
Oct4/Sox2/Klf4-infected MEFs	NYf4cG5vTnWwY4Tpc44hSXO\|YYm=	MlfwNVAh\|ryP	MkDxNlgh\A>?	MVHEUXNQ	NUTsXpZyWHKxbX;0[ZMhVUWIczDy[ZBzd2e{YX3tbY5oKFS{YX7z[JVk\WRiYomgU4N1PCxiU3;4Nkwh[W6mIFvs[lQ>	NEW1S28yQTh\|OUC1OS=>
Sca-1+ HPC	NFnyb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojhNkDPxE1?	M3PzcVYh\A>?	NGjEcplFVVOR	MmL0V5lv\XKpaYP0bYNidGy7IIDyc41wfGW\|IGPjZU0yM8LiSGDDJJBzd2yrZnXyZZRqd25iYX7kJINwdG:weTDmc5Ju[XSrb36geI9o\XSqZYKge4l1cCCHR1[=	NEX5cnczOTZ{NEO0PC=>
HMC1.2	M{LpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;LRlMxKM7:TR?=	M1m4flczKGh?	M1LzWWROW09?	MYPS[YR2[2W\|IHPlcIwhe3W{dnn2ZYw>	MVeyNlA{QTNyMR?=
Endothelial cell(EC)	NHzIVYZHfW6ldHnvckBCe3OjeR?=	M4TNNVMh\|ryP		MWDEUXNQ	MlfxVJJwdW:2ZYOg[Y5ld3SqZXzpZYwh[2WubDCoSWMqKGSrZn\ldoVvfGmjdHnvci=>	MU[yNlA2OjByNh?=
PANC1	M{GwdmFxd3C2b4Ppd{BCe3OjeR?=	NV3Z[GlZyqB3IN88US=>	MY[3NkBp	NWHuWpNuTE2VTx?=	NFPFT\|VVemmpZ3Xyd{BidiCjcH;weI91cWNicnXzdI9ve2V?	M165PFIzOjBzMUi2
INS-1E	NH;MPXpHfW6ldHnvckBCe3OjeR?=	MnfPNk42KM7:TR?=	M{DSSFI1KGh?	MkPkSG1UVw>?	NXfvdoxoUW6mdXPld{BiKHKnZIXjeIlwdiCxZjDOVFEhd3[ncnX4dJJme3Orb36=	NH3ZZ3ozOjR{N{ewOC=>
hiPSC-NPs	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXufGw{6oDLzszN	NV\rXoZNPzJiaB?=	NYi0NIZ2TE2VTx?=	NHq0TGtKdmO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vyqB?	MYCyNlY1OjZ6Nx?=
platelets	NHPITJlHfW6ldHnvckBCe3OjeR?=	Ml3INVAh\|ryP	M2e1NFE2KG2rbh?=	NHX2SoZFVVOR	MWXJcoNz\WG\|ZYOgeIhzd22kaX6tcYVlcWG2ZXSgdIxifGWuZYSgZYdoemWpYYTpc44h[W6mIFHUVEB{\WO{ZYTpc44>	M1;C[lI{OjN7OEe3
DN3	MVvGeY5kfGmxbjDBd5NigQ>?	NYjGc5RkOTBizszN	NW\uOmhXQTZiaB?=	MkPSSG1UVw>?	NGj6dZNKdmO{ZXHz[ZMh[2WubDDk[ZZmdG:ybXXueEBidmRicILvcIln\XKjdHnvci=>	MVmyN\|UzPjl6OR?=
embryonic stem cells (ESC)	NGf3fmlHfW6ldHnvckBCe3OjeR?=	NFyybGM{KML3TR?=	MUmxNUBl	MVvEUXNQ	M1W1fXBzd22xdHXzJJNmdGZvcnXu[ZdidCCxZjDuZeOwfmVvdInw[UBud3W\|ZTDlcYJzgW:waXOgd5RmdSClZXzsd{ApTVOFKR?=	NXq0O5JGOjN6NEOzNVI>
H460	NUTDNYlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjHO2J2PSEEtV2=	Ml3sNlQhcA>?	MlKzSG1UVw>?	M373ZnBzd22xdHXzJINmdGxicILvcIln\XKjdHnvci=>	MnfyNlQ{Pjd4OEi=
H157	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vnU\|UhyrWP	NFrS[mozPCCq	M1rqRWROW09?	NG\jV5lRem:vb4Tld{Bk\WyuIIDyc4xq\mW{YYTpc44>	MXGyOFM3PzZ6OB?=
H460	MV7BdI9xfG:\|aYOgRZN{[Xl?	M3flVVUhyrWP	M1TGd\|I1KGh?	MnW2SG1UVw>?	M2DrdWF1fGWwdXH0[ZMh[2WubDDhdI9xfG:\|aYO=	NXL4ZpVnOjR\|Nke2PFg>
H157	NYT3UGZ5SXCxcITvd4l{KEG\|c3H5	MYi1JOK2VQ>?	NILENmwzPCCq	NH\4[WZFVVOR	MUHEc4V{KG6xdDDzbYdvcW[rY3HueIx6KGGoZnXjeEBieG:ydH;zbZM>	MWSyOFM3PzZ6OB?=
A549	NVjFbGRTSXCxcITvd4l{KEG\|c3H5	Mne2OUDDvU1?	NULZZ4hoOjRiaB?=	NInkOldFVVOR	NE\WZ3dKdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYO=	NXXOelMzOjR\|Nke2PFg>
Neural progenitor cells	MVnGeY5kfGmxbjDBd5NigQ>?	NETEPVI{KM7:TR?=	MXyxNEBl	MYjEUXNQ	NIjSUINKdmS3Y3XzJIdmdmW{YYTpc44hd2ZibnX1doFtKHC{b3flcol1d3JiY3XscJM>	MXWyOFY{QDB\|NB?=
ES-D3	MWDDfZRwfG:6aXOgRZN{[Xl?	NYLGTIxnOTEEoN88US=>	NGe2UXk{KGR?	NWj4fnl1TE2VTx?=	MXnJcoR2[2W\|IH3v[IVz[XSnIHP5eI91d3irY3n0fUB4cXSqIFnDOVAhd2ZiND65JO69VQ>?	NU\pPZlFOjR5N{mzOlU>
ES-CCE	MmH1R5l1d3SxeHnjJGF{e2G7	NWCzeWN1OTEEoN88US=>	Mnn5N{Bl	NGDoV5JFVVOR	NXnhRY02UW6mdXPld{Bud2SncnH0[UBkgXSxdH;4bYNqfHl?	NVHQcZd{OjR5N{mzOlU>
ES-D3	NGLsRppHfW6ldHnvckBCe3OjeR?=	M13N[lXDqM7:TR?=	MV6zJIQ>	NHnJbXdFVVOR	NWK4XJRoW3S{b37ncJkhcW6mdXPld{B1cGViYXP0bZZqfHlib3[gW451N2KndHGtZ4F1\W6rbjDwZZRpf2G7	MVqyOFc4QTN4NR?=
ES-CCE	M3TJWWZ2dmO2aX;uJGF{e2G7	NEHBWWE2yqEQvF2=	M1W3NFMh\A>?	M2LtWWROW09?	NXfJS4d7W3S{b37ncJkhcW6mdXPld{B1cGViYXP0bZZqfHlib3[gW451N2KndHGtZ4F1\W6rbjDwZZRpf2G7	M2jhclI1Pzd7M{[1
SW982	NEnZdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jtU2lEPTB;MD6yNVQyPiEQvF2=	MWTTRW5ITVJ?
GCT	M1LYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3focmlEPTB;MD6zNFY4OiEQvF2=	NVfiNYhrW0GQR1XS
769-P	NGDTOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\0WI9KSzVyPUCuOVg1QTlizszN	MXTTRW5ITVJ?
LOXIMVI	NFz6[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfKTWM2OD1yLkW4PFMzKM7:TR?=	NF;kTnFUSU6JRWK=
D-336MG	NVTLU\|JyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13q[GlEPTB;MD64OFYzKM7:TR?=	MX\TRW5ITVJ?
S-117	NFvwV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwOUKxN\|Eh\|ryP	MXTTRW5ITVJ?
D-247MG	NITkNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TJVmlEPTB;MD65OFg2OiEQvF2=	Mn\wV2FPT0WU
TYK-nu	M3TKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PmT2lEPTB;MT6wO\|kyOiEQvF2=	MYHTRW5ITVJ?
A498	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M16wW2lEPTB;MT6zNFQ3QSEQvF2=	MnXqV2FPT0WU
BCPAP	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7jVZZKSzVyPUGuOlY5QThizszN	MUjTRW5ITVJ?
KYSE-180	NX\uNI5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlS2TWM2OD1zLkeyO\|g5KM7:TR?=	Ml7oV2FPT0WU
MIA-PaCa-2	M2C4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XVWmlEPTB;MT63OVk4PyEQvF2=	MmnRV2FPT0WU
HCC1395	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzNPG9KSzVyPUGuO\|gzPzNizszN	NVzqNm5ZW0GQR1XS
RS4-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrETWM2OD1zLkm1OFE2KM7:TR?=	NWPEfVk4W0GQR1XS
NCI-H2122	NHnTU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1niNWlEPTB;Mj6yO\|Y5PCEQvF2=	NHviTmZUSU6JRWK=
SNU-423	NX75XldOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTJwNEm3PFch\|ryP	NU\PfVYzW0GQR1XS
SK-LMS-1	NVfkbodOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJwNkSxNlgh\|ryP	MlLRV2FPT0WU
RPMI-7951	M1zLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;tV2pKSzVyPUKuO\|AyQTNizszN	NXP2WYJ6W0GQR1XS
COLO-829	NV;mdpA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;mcGlEPTB;Mj63OlU1KM7:TR?=	MkCzV2FPT0WU
SCC-9	NVzpPYNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPpb4hKSzVyPUKuPVU1QDVizszN	NUPWSJdwW0GQR1XS
A704	MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ftW2lEPTB;Mz6wPFEzKM7:TR?=	NVS1ZXg3W0GQR1XS
HOP-62	M4LuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUi2V2gzUUN3ME2zMlM3ODV2IN88US=>	NF7weYFUSU6JRWK=
HCC1569	MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnqbYVKSzVyPUOuOFg{ODVizszN	M330RnNCVkeHUh?=
A172	NUf0fIZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\p[VBKSzVyPUOuO\|U1QThizszN	NUnBRlhmW0GQR1XS
MOLT-16	M3qyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoT6TWM2OD1\|Lki4OVU3KM7:TR?=	M3n2d3NCVkeHUh?=
TE-15	NVm5eXFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;DPIw3UUN3ME2zMlk2OzR\|IN88US=>	NInOZWZUSU6JRWK=
OE19	M4q2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjKOppiUUN3ME2zMlk3PDVzIN88US=>	MkizV2FPT0WU
MHH-ES-1	M2\DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3X3bGlEPTB;ND6wOFU1PSEQvF2=	NILnUnhUSU6JRWK=
NKM-1	NE\vU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHzc5k5UUN3ME20MlE{QTdzIN88US=>	NFXEOZJUSU6JRWK=
RCC10RGB	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDCTWM2OD12LkK5OFc6KM7:TR?=	MXfTRW5ITVJ?
BxPC-3	NYTPb\|diT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DLUWlEPTB;ND63NFM6OSEQvF2=	M{\t[3NCVkeHUh?=
ALL-PO	NXnyRlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTRwOEO4OVgh\|ryP	M1[xfXNCVkeHUh?=
SK-OV-3	M2DFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHETWM2OD12Lkm5N\|Qh\|ryP	NHjXUolUSU6JRWK=
SW1710	M2XaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDUTWM2OD13LkSyOFU3KM7:TR?=	M3f3OnNCVkeHUh?=
NCI-H2452	MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXoTWM2OD13LkS1OlI5KM7:TR?=	MmK2V2FPT0WU
D-392MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTVwNEmxOFUh\|ryP	M1zZVHNCVkeHUh?=
LB2518-MEL	M3KxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\LcmlEPTB;NT63NlYzPyEQvF2=	NITX[HZUSU6JRWK=
BL-41	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmCyTWM2OD13LkixNlY3KM7:TR?=	NXXheYhKW0GQR1XS
WM-115	NH35OopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrlTWM2OD13LkixOVA6KM7:TR?=	Mk\QV2FPT0WU
SK-MEL-2	NUfHPZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXOTWM2OD14LkO4N\|Q1KM7:TR?=	NF7wUmhUSU6JRWK=
CGTH-W-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTZwNEG3JO69VQ>?	MWjTRW5ITVJ?
BB65-RCC	M2P3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XuNWlEPTB;Nj61N\|E6PSEQvF2=	MXPTRW5ITVJ?
CAL-85-1	NFHCTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DB[GlEPTB;Nj62NFk{PiEQvF2=	Mn6xV2FPT0WU
RT-112	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4S1O2lEPTB;Nz6xOlQ2PiEQvF2=	MlPpV2FPT0WU
MC116	M3TyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LNTWlEPTB;Nz6yPFY6OSEQvF2=	NW\xelZsW0GQR1XS
G-361	NGXXcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[5SWlEPTB;Nz60OlU3OSEQvF2=	NGTWSXlUSU6JRWK=
SW1417	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkO3TWM2OD15Lk[0OVg1KM7:TR?=	M2\4[XNCVkeHUh?=
MV-4-11	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\WWJVKSzVyPUiuOVQ{ODRizszN	MXjTRW5ITVJ?
CAL-72	NFTkdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;YTWM2OD16Lke2NVE{KM7:TR?=	MXXTRW5ITVJ?
MKN28	NILxbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRThwOEi1NVYh\|ryP	MUTTRW5ITVJ?
MEG-01	NEPGTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzMeFc2UUN3ME24Mlk6ODR\|IN88US=>	M{nod3NCVkeHUh?=
ACHN	M3GweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFL2VFBKSzVyPUmuN\|A2PDZizszN	M3vWTnNCVkeHUh?=
NCI-H1755	NETIPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLERpY1UUN3ME25MlM6QTh4IN88US=>	MkDQV2FPT0WU
NCI-H64	NV\x[21YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1z1R2lEPTB;OT60NlI2PSEQvF2=	M{PWeHNCVkeHUh?=
COLO-205	NEjLSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PlcmlEPTB;OT60N\|gzOSEQvF2=	NYfVXZZKW0GQR1XS
CTV-1	NEm1XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HpXGlEPTB;OT60N\|g6PCEQvF2=	NIrnVodUSU6JRWK=
U-2-OS	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LJcWlEPTB;OT60OVAxPiEQvF2=	MmXLV2FPT0WU
LB996-RCC	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYj6Xpo4UUN3ME25MlUzOzl5IN88US=>	M3fNNXNCVkeHUh?=
SK-N-DZ	NYK4UpVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTlwNkW3OFIh\|ryP	NXjBZpRLW0GQR1XS
EFM-19	NF;VWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXPR\|drUUN3ME25Mlc2PTZ4IN88US=>	NXT5VnFQW0GQR1XS
DBTRG-05MG	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1O3fmlEPTB;OT63O\|c4KM7:TR?=	M3LpRXNCVkeHUh?=
U-118-MG	NGX4VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLZTWM2OD17Lkm0OFQ1KM7:TR?=	MkjMV2FPT0WU
LB1047-RCC	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTlwOUm3PVgh\|ryP	M4nCfHNCVkeHUh?=
NCI-H28	NGTOS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPWTWM2OD1zMD60OFE{KM7:TR?=	MlTsV2FPT0WU
MZ2-MEL	M4nHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnYTWM2OD1zMD60Olc4KM7:TR?=	M2i4VXNCVkeHUh?=
M059J	NYnDSmgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3W4cmlEPTB;MUCuOlExOiEQvF2=	M{jLS3NCVkeHUh?=
HT-3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkP6TWM2OD1zMD62NVc6KM7:TR?=	MV\TRW5ITVJ?
SNU-387	MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTFyLkeyN\|Uh\|ryP	NHjlWWVUSU6JRWK=
NCI-H526	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFzLkGzOlUh\|ryP	NWftPGh6W0GQR1XS
HEL	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjPTWM2OD1zMT62OVc6KM7:TR?=	NHPUc5FUSU6JRWK=
PA-1	M4\WOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHyTWM2OD1zMT65N{DPxE1?	NIX2foVUSU6JRWK=
PC-14	NFLtW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DsVWlEPTB;MUKuN\|I1KM7:TR?=	MnTwV2FPT0WU
C8166	NV\aXWpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PDd2lEPTB;MUOuNlMyQCEQvF2=	NYjNc4x6W0GQR1XS
NCI-H82	NXzFeVJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofITWM2OD1zMz6yPVA6KM7:TR?=	M4Oy[XNCVkeHUh?=
DSH1	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnsbFFKSzVyPUGzMlM5PzlizszN	M{nGN3NCVkeHUh?=
T98G	NFWzU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rFfGlEPTB;MUOuOFcyPyEQvF2=	NWqyd3JuW0GQR1XS
KU812	M3jnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFX2OotKSzVyPUGzMlUyPzVizszN	MVHTRW5ITVJ?
SW48	NVTV[Y1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml64TWM2OD1zMz63NlY2KM7:TR?=	Mm\6V2FPT0WU
MEL-HO	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPGTWM2OD1zMz64PFI6KM7:TR?=	NWnzVmNlW0GQR1XS
SF539	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTifpRKUUN3ME2xOE4xOTF4IN88US=>	M2P6ZnNCVkeHUh?=
NB1	NWe3clRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvacHNKSzVyPUG0MlE6OzVizszN	NHTIfoxUSU6JRWK=
ST486	MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XGbWlEPTB;MUSuNlI2OSEQvF2=	MUXTRW5ITVJ?
LoVo	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rM[GlEPTB;MUWuNlY2QSEQvF2=	M{fZcHNCVkeHUh?=
NH-12	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF4LkCwPVch\|ryP	NHjtZ3ZUSU6JRWK=
CCRF-CEM	NYjURmNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnRTWM2OD1zNj62O\|AzKM7:TR?=	NGThfIlUSU6JRWK=
Daudi	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXNPYwzUUN3ME2xO{43OTR7IN88US=>	NF7PT5BUSU6JRWK=
SIMA	MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPl[25nUUN3ME2xO{46OTF6IN88US=>	MYDTRW5ITVJ?
8305C	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTleJZKSzVyPUG4MlU{ODVizszN	Ml62V2FPT0WU
EM-2	NW\lc5J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\yO\|RZUUN3ME2xPE43OjR6IN88US=>	NELpWIxUSU6JRWK=
SNU-449	NIDQSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;qRZFjUUN3ME2xPE44OTVizszN	NUH6cYxKW0GQR1XS
A101D	NGnqO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlewTWM2OD1zOT6yOFMh\|ryP	MUXTRW5ITVJ?
MHH-NB-11	NWjyNXY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonhTWM2OD1zOT61N\|QzKM7:TR?=	MnvPV2FPT0WU
Becker	NVnkcJZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17HfmlEPTB;MkCuNVc4PyEQvF2=	NGP4Vo9USU6JRWK=
NCI-H727	NYfn[o41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn2zTWM2OD1{MD6yNVY6KM7:TR?=	MYHTRW5ITVJ?
HCC1187	NV;pRo1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTJyLkO1PFkh\|ryP	NXO2ToFMW0GQR1XS
KYSE-450	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPMTWM2OD1{MT61N\|U1KM7:TR?=	MlLEV2FPT0WU
SK-MEL-28	M2qyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnEZ4tKSzVyPUKxMlY5PjNizszN	M2DaUHNCVkeHUh?=
BPH-1	Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLoTWM2OD1{MT63NFM2KM7:TR?=	MYXTRW5ITVJ?
EoL-1-	NXzWdWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlj2TWM2OD1{MT64N\|g2KM7:TR?=	MXHTRW5ITVJ?
TGBC24TKB	M37aUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlWzTWM2OD1{MT64PVU4KM7:TR?=	MYTTRW5ITVJ?
KARPAS-299	NGjteYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFraV2RKSzVyPUKyMlE6PTRizszN	MnnoV2FPT0WU
SW684	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzrOYRKUUN3ME2yNk4zQDV6IN88US=>	NH7keIVUSU6JRWK=
RXF393	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTJ{Lk[wOlgh\|ryP	NH;qRnlUSU6JRWK=
LS-513	NXrVZW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX3TWM2OD1{Mj62NVkzKM7:TR?=	NUX4RpdUW0GQR1XS
KURAMOCHI	NEPtWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFT3T5lKSzVyPUKyMlcxPjlizszN	MXfTRW5ITVJ?
GI-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\NTWM2OD1{Mj63PFQyKM7:TR?=	NG\2O2lUSU6JRWK=
M14	NUG1cohxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojRTWM2OD1{Mz6xNVMzKM7:TR?=	NEPxfYVUSU6JRWK=
REH	NYnmZmlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjOZ3UxUUN3ME2yN{4yPjl7IN88US=>	M{DU[3NCVkeHUh?=
K5	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmraTWM2OD1{Mz61OFg3KM7:TR?=	M{TkRXNCVkeHUh?=
PANC-10-05	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVe4fot[UUN3ME2yOE4xQDl6IN88US=>	MXTTRW5ITVJ?
HMV-II	NVy2Ull4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHW5W5hKSzVyPUK0MlIyPjNizszN	NIjORWlUSU6JRWK=
NCI-H1963	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPlTWM2OD1{ND6yPFM6KM7:TR?=	NXPYblFiW0GQR1XS
LU-139	NV75RlN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnzU\|FKSzVyPUK0Mlg{PSEQvF2=	NXjLdJNtW0GQR1XS
KASUMI-1	NXvK[mZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\2ZnlKSzVyPUK0Mlk{OjhizszN	NXzKNHhqW0GQR1XS
RO82-W-1	M{DVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTJ4LkezO\|ch\|ryP	NX;pcnk5W0GQR1XS
NCI-H1770	NHOxR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofwTWM2OD1{Nj64PVg3KM7:TR?=	NXy4NnAzW0GQR1XS
SNG-M	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrmTWM2OD1{Nz6yNlcyKM7:TR?=	M4C4WnNCVkeHUh?=
KLE	NUjLVJlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;H[Y5iUUN3ME2yO{4zPTZ3IN88US=>	NFLHTm5USU6JRWK=
NCI-H2170	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfR[mZKSzVyPUK3MlUzQDJizszN	MX3TRW5ITVJ?
COLO-792	NVryXWxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTiNXJKSzVyPUK3Mlc4OjhizszN	MkHnV2FPT0WU
ES8	NHHlNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\M[WlEPTB;MkeuO\|gyPCEQvF2=	NE\N[Y9USU6JRWK=
MC-CAR	MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJ5Lke5NFch\|ryP	M2HGZXNCVkeHUh?=
SU-DHL-1	NInpd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrwTWM2OD1{Nz65OFc1KM7:TR?=	NWHiZVJVW0GQR1XS
OAW-28	NF3HeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXMRVJRUUN3ME2yPE4xODV{IN88US=>	NVfrW2VQW0GQR1XS
C32	M3TCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jiNGlEPTB;MkiuNFgzPiEQvF2=	MlHJV2FPT0WU
SW872	M3vZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXme3RKSzVyPUK4MlU{OjZizszN	NWfRcopiW0GQR1XS
JiyoyeP-2003	NWTydpVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Xvd2lEPTB;MkmuOlcyQSEQvF2=	MlvlV2FPT0WU
A204	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYO1bGR4UUN3ME2yPU43QDJ6IN88US=>	MWPTRW5ITVJ?
IST-MES1	M4T0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU[0PZZDUUN3ME2yPU44ODl{IN88US=>	NXH5TnpnW0GQR1XS
LCLC-103H	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3UVI14UUN3ME2zNE4zODV7IN88US=>	NVKxT\|F4W0GQR1XS
CAKI-1	NFrBbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfT[ZJKSzVyPUOwMlI3PTZizszN	NHP1T4NUSU6JRWK=
NALM-6	NF7ZcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\0N3RKSzVyPUOwMlQ6PjVizszN	NYDBU\|BGW0GQR1XS
SK-MM-2	MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULsR5VVUUN3ME2zNE46Pzl{IN88US=>	NUTLd3llW0GQR1XS
LB373-MEL-D	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LwRmlEPTB;M{GuNFA1PyEQvF2=	M{XhZ3NCVkeHUh?=
CAS-1	NXzGWow6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{CzS2lEPTB;M{GuO\|Y3PSEQvF2=	MUfTRW5ITVJ?
KNS-42	NU\mXVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm[xTWM2OD1\|MT64OlYzKM7:TR?=	NELxTIdUSU6JRWK=
SW948	NVfqdZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LyWmlEPTB;M{KuO\|U1QCEQvF2=	M4nObXNCVkeHUh?=
HCC1143	NXftU2tRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTN{Lke5O\|kh\|ryP	MnW0V2FPT0WU
NCI-H1648	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnmyTWM2OD1\|Mj64OFY4KM7:TR?=	M1rFfXNCVkeHUh?=
RVH-421	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILtSmRKSzVyPUOzMlE3QCEQvF2=	M{[1OXNCVkeHUh?=
KU-19-19	NHnrOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTN\|Lke1N\|Qh\|ryP	M{PSPXNCVkeHUh?=
PFSK-1	NYWze2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vRTGlEPTB;M{SuPVI1OSEQvF2=	NYe0eVJ4W0GQR1XS
TK10	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrSfFgzUUN3ME2zOU4yOzJ{IN88US=>	Moq5V2FPT0WU
IGROV-1	M2LV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TTc2lEPTB;M{WuN\|QyPiEQvF2=	M2nN[nNCVkeHUh?=
EFE-184	NFTvPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnRcng{UUN3ME2zOU46OTdizszN	NUPte\|hyW0GQR1XS
8505C	NUP3TVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTN3LkmyPVQh\|ryP	NFr3[IJUSU6JRWK=
SK-UT-1	NYrzXmFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnv6TWM2OD1\|Nj6zN\|MyKM7:TR?=	NF3MOHdUSU6JRWK=
MKN1	M{ToSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTN4Lki0OFQh\|ryP	M16xV3NCVkeHUh?=
no-10	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFuwRVhKSzVyPUO4MlEzQTRizszN	NUDp[VBnW0GQR1XS
HT-144	M33wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXTdZNkUUN3ME2zPE4zPTd3IN88US=>	MXfTRW5ITVJ?
CMK	MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LzSmlEPTB;M{iuOFE3OiEQvF2=	NFSxcGFUSU6JRWK=
KM12	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXJPZpZUUN3ME2zPE42QTl6IN88US=>	Mo\TV2FPT0WU
HCC2218	NGGxfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTRyLkW4OFkh\|ryP	Mn[3V2FPT0WU
BE-13	M2jpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LXTGlEPTB;NEGuOFQ4OyEQvF2=	MULTRW5ITVJ?
SK-CO-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTRzLke3OVUh\|ryP	M2\4fnNCVkeHUh?=
MPP-89	NYW3PWYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTRzLkmyNVEh\|ryP	MnHyV2FPT0WU
NY	NIT6fXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnuSW51UUN3ME20Nk4yQDBzIN88US=>	Mo\uV2FPT0WU
IST-MEL1	NFziZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XoT2lEPTB;NEKuOlk{QCEQvF2=	NIjNZ2tUSU6JRWK=
HCT-116	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfYUFVKSzVyPUSzMlIxQTlizszN	M1z3dHNCVkeHUh?=
LB831-BLC	NHjWZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2qzT2lEPTB;NEOuOlk4KM7:TR?=	M2LJSXNCVkeHUh?=
TE-8	MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTR\|Lke4PVUh\|ryP	MWnTRW5ITVJ?
SR	M3;KXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1y4cWlEPTB;NEOuPFY4OyEQvF2=	MVPTRW5ITVJ?
ESS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;PTWM2OD12ND6yNFYzKM7:TR?=	MVPTRW5ITVJ?
KYSE-270	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPUeWRKSzVyPUS1MlA1OzdizszN	M{HtfXNCVkeHUh?=
H4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrvTWM2OD12NT6zNlk3KM7:TR?=	M3S2TXNCVkeHUh?=
COLO-800	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXji[IFPUUN3ME20OU42QDl6IN88US=>	NHjXcJFUSU6JRWK=
Ramos-2G6-4C10	NILWV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoWwTWM2OD12Nj6wO\|U2KM7:TR?=	MoHLV2FPT0WU
no-11	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlG1TWM2OD12Nj6yNFMyKM7:TR?=	M{LORXNCVkeHUh?=
UACC-62	NUDLfZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTuTWM2OD12Nj64OlA5KM7:TR?=	NV7Wc41oW0GQR1XS
D-542MG	MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTR5LkS1PFkh\|ryP	M{DycnNCVkeHUh?=
NCI-H747	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTR5LkeyOlQh\|ryP	NEX3N2VUSU6JRWK=
HCC2998	M4\BR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\vcGlEPTB;NEiuNlk5OiEQvF2=	NV\vN2szW0GQR1XS
SNB75	NYrj[pFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrKTWM2OD12OD60NVE5KM7:TR?=	M{HTTnNCVkeHUh?=
COR-L105	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PRT2lEPTB;NEiuPVc{KM7:TR?=	MlK0V2FPT0WU
SNU-C1	NETQVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[1W5BKSzVyPUS5MlMzODdizszN	NIrVfppUSU6JRWK=
LC4-1	NF:1fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYS4ZYJxUUN3ME20PU45QTF{IN88US=>	MVfTRW5ITVJ?
KS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTVyLkKyNlUh\|ryP	MkLYV2FPT0WU
NCI-H1793	NITjXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\XdGlEPTB;NUGuNlMyKM7:TR?=	NHvMSXZUSU6JRWK=
NCI-H1650	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LRSGlEPTB;NUGuOVg1QSEQvF2=	M3e3[XNCVkeHUh?=
MCF7	M2W1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnYUXhKSzVyPUWxMlc2PTRizszN	MVjTRW5ITVJ?
SK-N-AS	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTVzLkiyPFEh\|ryP	NXrLdGltW0GQR1XS
SW837	M4rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPTOVhHUUN3ME21NU46Pzh3IN88US=>	MX\TRW5ITVJ?
DB	NUfibG8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nETmlEPTB;NUGuPVg2PSEQvF2=	M1zqdXNCVkeHUh?=
CESS	NGC4V2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkn1TWM2OD13Mj6xOFUh\|ryP	MoO3V2FPT0WU
CHP-126	NWC4VHNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7HTWM2OD13Mz61NVY6KM7:TR?=	MoPRV2FPT0WU
COLO-824	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTV\|Lk[5O\|Yh\|ryP	NGGxfXJUSU6JRWK=
MG-63	NVyyeHhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTV\|LkmzPFEh\|ryP	NULsR5BJW0GQR1XS
KGN	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHPPGxKSzVyPUWzMlk2QSEQvF2=	MoHuV2FPT0WU
697	NH7FVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTNWWFKSzVyPUW0MlE2PTVizszN	MY\TRW5ITVJ?
MC-IXC	M3rGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInhZpNKSzVyPUW0MlQ{PjRizszN	M{jNUXNCVkeHUh?=
A375	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vReGlEPTB;NUSuPFA2QSEQvF2=	MVXTRW5ITVJ?
LXF-289	M1K0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;rWGlEPTB;NUWuOVA3PiEQvF2=	NEPUZotUSU6JRWK=
ES6	M1[xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;Rc5ZHUUN3ME21OU45QDl7IN88US=>	NXnSOndQW0GQR1XS
DV-90	Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIe4V\|VKSzVyPUW1Mlg6OTdizszN	NWjLb\|ZFW0GQR1XS
RCM-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1H6VGlEPTB;NU[uNFA4QCEQvF2=	MkjlV2FPT0WU
NCI-H2405	NFHTS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTV4LkG2PVMh\|ryP	MV\TRW5ITVJ?
DoTc2-4510	NViyWoJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXP0UVZzUUN3ME21Ok43ODV5IN88US=>	Mkm2V2FPT0WU
RPMI-8866	NGTtVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\HUWlEPTB;NUeuNlQyOiEQvF2=	MX7TRW5ITVJ?
BV-173	NVj1fY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\XTWM2OD13Nz61NVQzKM7:TR?=	M3nQS3NCVkeHUh?=
LCLC-97TM1	MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzYXFdKSzVyPUW5MlA2PTNizszN	NE\pXWNUSU6JRWK=
HT-1376	MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXnTWM2OD13OT6wPVIyKM7:TR?=	M1HyTHNCVkeHUh?=
ACN	M{XtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HqT2lEPTB;NUmuNVU5PyEQvF2=	NWHEe41zW0GQR1XS
LU-134-A	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGW3fXVKSzVyPUW5MlYxOTZizszN	NXXjW\|Y1W0GQR1XS
SiHa	M{\3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2WzfmlEPTB;NUmuOlQ5PyEQvF2=	NFnBUFdUSU6JRWK=
EKVX	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\DTWM2OD14MT60PVU5KM7:TR?=	MYrTRW5ITVJ?
NMC-G1	M4T6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTETWM2OD14MT65NlQzKM7:TR?=	M1\UcHNCVkeHUh?=
NCI-H1734	NXLIVJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Oy[WlEPTB;NkGuPVY3OyEQvF2=	NVOxXGtEW0GQR1XS
K-562	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvaeHJjUUN3ME22Nk4zPDV{IN88US=>	MYDTRW5ITVJ?
T-24	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTOTVFKSzVyPU[yMlcyOjZizszN	Mn7QV2FPT0WU
SCH	NH\TcmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnqwTWM2OD14ND6yN\|UyKM7:TR?=	Mnu2V2FPT0WU
AN3-CA	NHG1W3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fE[GlEPTB;NkSuN\|A{PSEQvF2=	MU\TRW5ITVJ?
MFE-296	MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnWwTWM2OD14ND60OFc{KM7:TR?=	MVrTRW5ITVJ?
HuCCT1	NGDCfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\uVWhKSzVyPU[3MlA{PzRizszN	MUHTRW5ITVJ?
NCI-H1703	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7RTWM2OD14OD6xNVcyKM7:TR?=	NITWXIxUSU6JRWK=
C-4-II	NHfONHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTZ7LkO2NFch\|ryP	NE[1Z4NUSU6JRWK=
NCI-H2342	NHj2SJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTZ7LkO5OlEh\|ryP	M3fzUHNCVkeHUh?=
Hs-578-T	MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1G5c2lEPTB;N{CuN{DPxE1?	MoXMV2FPT0WU
HCC1806	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWn3fHBPUUN3ME23NU41PTh5IN88US=>	NIC0SIFUSU6JRWK=
EW-16	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUSyd49GUUN3ME23NU44PDF3IN88US=>	M{\1WHNCVkeHUh?=
KALS-1	NWrSemdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPwUZlKSzVyPUezMlU1PzVizszN	M2\FPXNCVkeHUh?=
RT4	NITOVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTd\|LkW3OFIh\|ryP	NUTnOG9HW0GQR1XS
LS-411N	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEexUI1KSzVyPUe0MlI2OjhizszN	NF71boxUSU6JRWK=
SK-MEL-1	NWjkfZBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYD6fI9pUUN3ME23OU45ODF7IN88US=>	NGjGOYhUSU6JRWK=
8-MG-BA	MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrvcFdKSzVyPUe2MlExQTZizszN	MWXTRW5ITVJ?
HSC-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVn0eGpMUUN3ME23O{4xOjh{IN88US=>	M{m0N3NCVkeHUh?=
NB6	M4n6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3ib3VtUUN3ME23PE4yOjl7IN88US=>	MYPTRW5ITVJ?
PANC-03-27	M1\5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonyTWM2OD15OD60N\|Uh\|ryP	NEjlfItUSU6JRWK=
KP-N-YS	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljlTWM2OD15OD61PFc5KM7:TR?=	M4HhbHNCVkeHUh?=
SF295	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nuSGlEPTB;N{muPVU2OyEQvF2=	NEi2[plUSU6JRWK=
HCE-T	NEPyfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{O2U2lEPTB;OECuNVU5QCEQvF2=	NFvtdINUSU6JRWK=
KYSE-410	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRThyLkK4OVch\|ryP	MUnTRW5ITVJ?
NB12	NWDoe283T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDHOpRKSzVyPUiwMlk{PjlizszN	MlLyV2FPT0WU
NCI-H661	NEHN[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nDdWlEPTB;OEGuN\|Q1KM7:TR?=	MXrTRW5ITVJ?
NCI-H1417	NUjlPZBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjQeVhNUUN3ME24NU41OzZ6IN88US=>	NWHW[JlzW0GQR1XS
KMOE-2	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRThzLki1N\|Eh\|ryP	M3vZRnNCVkeHUh?=
SW1573	M3vzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXRUGNCUUN3ME24Nk42QDl\|IN88US=>	NFTtTpZUSU6JRWK=
BFTC-905	M1nrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGT2WmlKSzVyPUi0MlAyPzJizszN	MX;TRW5ITVJ?
SBC-1	M3L5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rFNmlEPTB;OESuNFIxQCEQvF2=	M37S[XNCVkeHUh?=
MDA-MB-175-VII	NV\XNZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHCOG1yUUN3ME24OU44PDJ4IN88US=>	NWq5NYJ4W0GQR1XS
TE-12	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\mbVZKSzVyPUi5MlM4PDFizszN	M3PTTHNCVkeHUh?=
NCI-H650	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y1RWlEPTB;OEmuPFczPCEQvF2=	MmPUV2FPT0WU
C-33-A	M{P4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rjUmlEPTB;OUCuOVQh\|ryP	M4jnTnNCVkeHUh?=
MZ7-mel	M4DM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2e3TGlEPTB;OUGuNlY4PiEQvF2=	Mn;xV2FPT0WU
BOKU	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTl{Lk[5OVch\|ryP	MkTWV2FPT0WU
CAL-33	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPXTWM2OD17Mz6wOlAyKM7:TR?=	NGO3WZpUSU6JRWK=
23132-87	NHXEd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHzclNKSzVyPUmzMlE3QCEQvF2=	M3zoeHNCVkeHUh?=
J82	NXOySpVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2j6XWlEPTB;OUOuO\|gyOSEQvF2=	NHLXVlZUSU6JRWK=
MZ1-PC	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\v[WlEPTB;OUSuOVk5PCEQvF2=	MlG3V2FPT0WU
MEL-JUSO	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDLblRKSzVyPUm0Mlk2PCEQvF2=	MWXTRW5ITVJ?
RMG-I	MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzhTWM2OD17NT6xNFczKM7:TR?=	NHG1OolUSU6JRWK=
A2058	MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\iW4c3UUN3ME25OU41PjF5IN88US=>	M2XUWnNCVkeHUh?=
Caov-4	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonsTWM2OD17NT62PFUh\|ryP	M3TQVnNCVkeHUh?=
OS-RC-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\kOG9KSzVyPUm3MlQ3OSEQvF2=	MYnTRW5ITVJ?
MKN7	NV;VSHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTl5Lke0N\|kh\|ryP	NXO2fpdUW0GQR1XS
U-698-M	NYfqfoZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\kWnFKSzVyPUm4Mlk1QDlizszN	Ml;kV2FPT0WU
PC-3	Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHjOI1IUUN3ME25PU4xPTZ2IN88US=>	NY\LelVEW0GQR1XS
NCI-H292	M3vUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3mbVFQUUN3ME25PU4{ODB2IN88US=>	NGnmN2NUSU6JRWK=
IGR-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTl7LkOxNVkh\|ryP	NVTYcJFHW0GQR1XS
Mewo	NU\LV5hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4H5XWlEPTB;OUmuOVYxOyEQvF2=	NIPmb2FUSU6JRWK=
LU-65	NY\XeldsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1ThZWlEPTB;MUCxMlA5OSEQvF2=	MlPHV2FPT0WU
Saos-2	NYPJV4RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFyMT60N\|ch\|ryP	MUTTRW5ITVJ?
TE-11	NEmzdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;U[\|BCUUN3ME2xNFEvPzJ2IN88US=>	NIPCbnlUSU6JRWK=
SK-MES-1	NH\G[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf6dFllUUN3ME2xNFEvPzZ{IN88US=>	M3;EOHNCVkeHUh?=
KE-37	NHLK[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;1TWM2OD1zMEKuPVUh\|ryP	NWC4TGZUW0GQR1XS
MKN45	NXHSWnljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXBNZRKSzVyPUGwN{42QDRizszN	NF;MOZFUSU6JRWK=
UM-UC-3	NUnYS21qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXRVpJKSzVyPUGwN{45PDJizszN	NGryNW1USU6JRWK=
SNU-C2B	NWLQRYJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFyNT6wNlMh\|ryP	NIfuT41USU6JRWK=
RPMI-8226	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7v[oNIUUN3ME2xNFYvPjd6IN88US=>	NXm5cVZEW0GQR1XS
PANC-08-13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkX6TWM2OD1zME[uPFUh\|ryP	M1rETnNCVkeHUh?=
NCI-H23	M3TWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml:zTWM2OD1zMEiuN\|U4KM7:TR?=	NH7lTFlUSU6JRWK=
HOP-92	NXnlXWFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLaSItuUUN3ME2xNFgvPDd3IN88US=>	MUPTRW5ITVJ?
FTC-133	NF[5XWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{i0XGlEPTB;MUC4MlQ5QCEQvF2=	MlP2V2FPT0WU
D-263MG	M3KyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1X1OWlEPTB;MUC4Mlk3OSEQvF2=	Mmr0V2FPT0WU
DU-145	NH7iO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTvUYNKSzVyPUGwPU46PDVizszN	MmPkV2FPT0WU
A253	NXHnNIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTFzMD60O\|kh\|ryP	NIP3OGFUSU6JRWK=
HCT-15	NX;LRYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTFzMD62OlEh\|ryP	M36zbHNCVkeHUh?=
WSU-NHL	M3Pub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\0dm9KSzVyPUGxNk4xOSEQvF2=	Ml7XV2FPT0WU
U031	NFfxNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3JZVYyUUN3ME2xNVIvODZ3IN88US=>	NVTKUHNsW0GQR1XS
MDA-MB-157	M1WwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTFzMj60PUDPxE1?	NGPacXNUSU6JRWK=
NEC8	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIi2[o9KSzVyPUGxNk43OjRizszN	M1XmTXNCVkeHUh?=
SIG-M5	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTFzMz6xNlUh\|ryP	MWnTRW5ITVJ?
786-0	NV\pdoRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\wTWM2OD1zMUOuOFU{KM7:TR?=	M{TMfHNCVkeHUh?=
DMS-273	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\XOZhKSzVyPUGxOU43OTdizszN	M4Pld3NCVkeHUh?=
Calu-6	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGD5OVBKSzVyPUGxOk44QThizszN	NFXmNoRUSU6JRWK=
HCC1599	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[0bmNHUUN3ME2xNVcvOTV4IN88US=>	NE\PNnhUSU6JRWK=
OVCAR-8	NFvueW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTFzNz62Olgh\|ryP	MkD3V2FPT0WU
ATN-1	NILsNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEP5OFBKSzVyPUGxO{45OjhizszN	MWTTRW5ITVJ?
RKO	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PFXGlEPTB;MUG3Mlg6QCEQvF2=	M1zURnNCVkeHUh?=
SKG-IIIa	NWLrNZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPzbmVKSzVyPUGxPE4yOTZizszN	MoLZV2FPT0WU
SUP-T1	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojOTWM2OD1zMUiuPVU3KM7:TR?=	MUPTRW5ITVJ?
KNS-81-FD	NVz0fYlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzW[HBKSzVyPUGxPU41OTdizszN	MnzKV2FPT0WU
OVCAR-3	MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlS3TWM2OD1zMUmuPVE2KM7:TR?=	M1rvc3NCVkeHUh?=
NCI-N87	NHLMT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2L3d2lEPTB;MUKxMlA1PCEQvF2=	NWXxeXpOW0GQR1XS
HuP-T4	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jtUmlEPTB;MUKxMlU2KM7:TR?=	MULTRW5ITVJ?
KYSE-140	M2m0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXVTWM2OD1zMkKuNVQyKM7:TR?=	NY\4SHg{W0GQR1XS
HAL-01	NHP1NlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:0XJNtUUN3ME2xNlIvPDl7IN88US=>	Ml;CV2FPT0WU
HT-29	NY\MRnFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTF{Mj63O\|gh\|ryP	MXHTRW5ITVJ?
OPM-2	NWC4NGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDrNmpKUUN3ME2xNlMvOTd4IN88US=>	Mly5V2FPT0WU
SW1463	M1m2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1X2PGlEPTB;MUK0MlA4PyEQvF2=	M4LzXHNCVkeHUh?=
NCI-H2087	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnlO3dKSzVyPUGyOE4zQDNizszN	NIHXZXpUSU6JRWK=
UMC-11	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\yTGlEPTB;MUK2MlA{QCEQvF2=	M3fXeHNCVkeHUh?=
EB-3	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF{Nz6wNVMh\|ryP	NI\jTXNUSU6JRWK=
HEC-1	NV33N2k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnRSIdKSzVyPUGyPU4yQThizszN	NUL2dFRrW0GQR1XS
LU-99A	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LzOmlEPTB;MUK5Mlk{OSEQvF2=	M3H5T3NCVkeHUh?=
VMRC-RCZ	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HzWWlEPTB;MUOwMlM4PSEQvF2=	MkHQV2FPT0WU
MFH-ino	NVfYW2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDwZYlKSzVyPUGzNU4yOTRizszN	MUTTRW5ITVJ?
HT-1080	NFTWWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUT2cG15UUN3ME2xN\|IvOjB2IN88US=>	NHy2O2hUSU6JRWK=
CTB-1	NHLrUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\W[2lEPTB;MUOyMlg6PyEQvF2=	NI\keGZUSU6JRWK=
Capan-2	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Tt[WlEPTB;MUOzMlk4PSEQvF2=	MmL5V2FPT0WU
BB30-HNC	NYjPd5ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3UcIdFUUN3ME2xN\|QvOTF4IN88US=>	MoLIV2FPT0WU
CP50-MEL-B	M4TVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjlTWM2OD1zM{SuNkDPxE1?	NH;JbWtUSU6JRWK=
JEG-3	NXrEVWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nVUmlEPTB;MUO0MlM2QSEQvF2=	MVfTRW5ITVJ?
NCI-H1437	NFX2XZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XaN2lEPTB;MUO0MlU6KM7:TR?=	MYrTRW5ITVJ?
NOS-1	NXzmV2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1S5OmlEPTB;MUO0Mlc3PSEQvF2=	NFSzN3pUSU6JRWK=
G-402	NFSwV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVz4XnNyUUN3ME2xN\|UvOjl3IN88US=>	MlznV2FPT0WU
OAW-42	NY\4RpRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXrOI9KSzVyPUGzO{45PTZizszN	M4i5Z3NCVkeHUh?=
Ca-Ski	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrTTWM2OD1zM{iuPFMyKM7:TR?=	NHvsdZVUSU6JRWK=
BHT-101	NWnUWZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DqUGlEPTB;MUSwMlIxQCEQvF2=	NVTUZVl3W0GQR1XS
OVCAR-4	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI[3UZdKSzVyPUG0NE44PDlizszN	NGLCOFBUSU6JRWK=
Detroit562	M1nHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvUXYtwUUN3ME2xOFEvPDZ4IN88US=>	NHXuenBUSU6JRWK=
OCI-AML2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37kXmlEPTB;MUSxMlUxPyEQvF2=	M2TjfXNCVkeHUh?=
OE33	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTF2MT63PVgh\|ryP	M4LkXXNCVkeHUh?=
YKG-1	NFPZWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\aSmlEPTB;MUSyMlg5QSEQvF2=	MoXLV2FPT0WU
CCF-STTG1	M1jqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjReW9KSzVyPUG0N{4{OzRizszN	MWPTRW5ITVJ?
NCI-H810	NFnOTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjzUG5KSzVyPUG0N{43QDdizszN	M{LMRnNCVkeHUh?=
SCC-25	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXPWWI6UUN3ME2xOFQvODB3IN88US=>	NFfzSYdUSU6JRWK=
HTC-C3	NF7XVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjlUllzUUN3ME2xOFUvODd3IN88US=>	M1PCeXNCVkeHUh?=
G-401	M1XyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX4U4dKSzVyPUG0OU45OzVizszN	NET0fW5USU6JRWK=
OMC-1	NInpTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTF2NT65Olch\|ryP	M{DiUnNCVkeHUh?=
LK-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTF2Nz6xOFMh\|ryP	M3u5TXNCVkeHUh?=
SW13	M4fPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorNTWM2OD1zNEeuNlU{KM7:TR?=	M2PpV3NCVkeHUh?=
BB49-HNC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jiV2lEPTB;MUS3MlQxPCEQvF2=	M3;sRXNCVkeHUh?=
DMS-114	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF2Nz60OFEh\|ryP	NGfFd3FUSU6JRWK=
GCIY	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTF2Nz63PVch\|ryP	NHP1RWVUSU6JRWK=
GAMG	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvGTWM2OD1zNEiuNlQ4KM7:TR?=	MnW5V2FPT0WU
KYSE-520	M4e4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTkfFdwUUN3ME2xOFgvPTRizszN	M16ycnNCVkeHUh?=
LB647-SCLC	MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF2OD61OlIh\|ryP	NXjIcI0{W0GQR1XS
639-V	NFSySVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHUXWhKSzVyPUG0PE44ODVizszN	Moi3V2FPT0WU
TE-9	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTF2OT60OFMh\|ryP	Mki0V2FPT0WU
Caov-3	M4Lwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PFTmlEPTB;MUS5MlcyPCEQvF2=	M13rcHNCVkeHUh?=
L-540	M4LBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\CSGlEPTB;MUS5Mlc2KM7:TR?=	MWrTRW5ITVJ?
NCI-H748	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlezTWM2OD1zNUCuNlA6KM7:TR?=	MnvIV2FPT0WU
GDM-1	Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrGZZBKSzVyPUG1NU4yOzVizszN	MULTRW5ITVJ?
GAK	NGe0SXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zFUGlEPTB;MUWxMlM4PCEQvF2=	MlzOV2FPT0WU
AsPC-1	NIjk[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzLUlJKSzVyPUG1Nk44PjRizszN	MWXTRW5ITVJ?
MDA-MB-361	NH3lW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzJTWM2OD1zNUOuNVY1KM7:TR?=	M4flVHNCVkeHUh?=
TT	M2\HNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fQPGlEPTB;MUWzMlQ6KM7:TR?=	M1z3UHNCVkeHUh?=
Calu-1	NH7hcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGf3XpdKSzVyPUG1OE4xODNizszN	NI[xTYlUSU6JRWK=
RERF-LC-MS	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTF3ND63O\|Ih\|ryP	MofMV2FPT0WU
DK-MG	M{PhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDaTWM2OD1zNUWuNVg{KM7:TR?=	MYTTRW5ITVJ?
CAL-120	NXzkZ4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2GyW2lEPTB;MUW1MlgzOSEQvF2=	MmezV2FPT0WU
HCC1419	NHvBbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF3Nj6wO\|ch\|ryP	M1PGN3NCVkeHUh?=
DG-75	NH\LdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnoR2NoUUN3ME2xOVYvPjl2IN88US=>	MkHXV2FPT0WU
HCC38	M{nhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHG2RlVKSzVyPUG1O{4{PjlizszN	NX7peo9GW0GQR1XS
HCC70	M3Lrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPldVdLUUN3ME2xOVkvOjR{IN88US=>	NHzu[FVUSU6JRWK=
ES4	NITMZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDNTWM2OD1zNUmuN\|k3KM7:TR?=	MX;TRW5ITVJ?
NCI-H2052	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HwemlEPTB;MUW5MlU5OyEQvF2=	NUPBRW1uW0GQR1XS
EFO-27	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlm1TWM2OD1zNkCuOVg1KM7:TR?=	NFP2e4tUSU6JRWK=
CAL-62	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni4TWM2OD1zNkKuOlE{KM7:TR?=	NWfybm5TW0GQR1XS
CHP-212	M4fjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1raSWlEPTB;MU[zMlYzPiEQvF2=	NV72THI4W0GQR1XS
AU565	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrITWM2OD1zNkOuOlQh\|ryP	M17i[HNCVkeHUh?=
Ca9-22	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1v4cWlEPTB;MU[0MlMzOSEQvF2=	NH62RpVUSU6JRWK=
EFO-21	M3zjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUeyOmF[UUN3ME2xOlUvPDVizszN	NVnuOnlxW0GQR1XS
KINGS-1	NX:5dG0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHDTWM2OD1zNkeuN\|U1KM7:TR?=	NX;PbWF[W0GQR1XS
JVM-2	NXTMdZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvvfJFKSzVyPUG2O{41PTFizszN	M2rWeHNCVkeHUh?=
OVCAR-5	NFLLZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF4OD6zNFkh\|ryP	NEfvcG1USU6JRWK=
Calu-3	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGL3OFdKSzVyPUG2PE4{OTFizszN	NIrCdZNUSU6JRWK=
CP66-MEL	NXPnXJpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1H6bmlEPTB;MU[4MlQyPSEQvF2=	NF\OTG9USU6JRWK=
KYSE-150	NX73Sm5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTF4OT62N\|Yh\|ryP	MWjTRW5ITVJ?
Daoy	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjJdpd{UUN3ME2xOlkvQDlzIN88US=>	NUXzTphrW0GQR1XS
HUTU-80	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF5MT6wN\|Ih\|ryP	Mo[5V2FPT0WU
SW620	M{LVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmntTWM2OD1zN{GuOVM2KM7:TR?=	NUKxNWNsW0GQR1XS
HuO-3N1	MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjVVFk4UUN3ME2xO\|IvOjd\|IN88US=>	M1zM[HNCVkeHUh?=
HH	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVToOnd{UUN3ME2xO\|MvQDR6IN88US=>	MkTqV2FPT0WU
ME-180	NVHacVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXL3RoJXUUN3ME2xO\|QvODF4IN88US=>	NHHvWVdUSU6JRWK=
SW756	NX7Sc3FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3ETWM2OD1zN{SuPFY{KM7:TR?=	MULTRW5ITVJ?
LNCaP-Clone-FGC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILGdVJKSzVyPUG3OU45PjFizszN	M1nmWXNCVkeHUh?=
YT	NIPSZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnHW2NxUUN3ME2xO\|YvOzl7IN88US=>	NUG2OJhxW0GQR1XS
EW-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTF5Nj61OVUh\|ryP	MXrTRW5ITVJ?
COLO-741	NXnCNpRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnkbnFKSzVyPUG3O{42PjFizszN	MV;TRW5ITVJ?
SK-NEP-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zMfWlEPTB;MUe3MlgxPiEQvF2=	MmHrV2FPT0WU
NB10	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInhcFJKSzVyPUG3O{45PDZizszN	MmPEV2FPT0WU
SF126	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\6VHFKSzVyPUG3PU41OzJizszN	MWLTRW5ITVJ?
NCI-H522	MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTF6MT6wOVkh\|ryP	NX3O[olEW0GQR1XS
PSN1	M2L1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfHfotKSzVyPUG4NU43PiEQvF2=	NF3aUWdUSU6JRWK=
GI-ME-N	NV7ncVBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDDdIVNUUN3ME2xPFEvPjd{IN88US=>	MUfTRW5ITVJ?
SBC-5	M4izd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XUfGlEPTB;MUixMlk{PCEQvF2=	NXn6UHhwW0GQR1XS
ONS-76	M2O3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LKVmlEPTB;MUiyMlM5PyEQvF2=	Mmq4V2FPT0WU
LOUCY	M{HtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmf5TWM2OD1zOEKuOlg5KM7:TR?=	MX7TRW5ITVJ?
SN12C	NHnpS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXL2O5FbUUN3ME2xPFIvQDJ7IN88US=>	MkHCV2FPT0WU
A427	MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUmyd\|dFUUN3ME2xPFQvPjNzIN88US=>	NInKZmFUSU6JRWK=
DOK	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF75[FFKSzVyPUG4OE43PDNizszN	NWTHdGlRW0GQR1XS
MDA-MB-415	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTF6ND62OVEh\|ryP	NUK1doxFW0GQR1XS
MRK-nu-1	M4\odGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTF6ND65O\|Ih\|ryP	NV;rTI5EW0GQR1XS
LB2241-RCC	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPWN\|BKSzVyPUG4OU4yPDVizszN	MVLTRW5ITVJ?
NCI-H1563	M2fvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\WVGRKSzVyPUG4OU4zODlizszN	M1XDc3NCVkeHUh?=
MDA-MB-453	NGHKNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\iVZJKSzVyPUG4Ok46PDFizszN	MVTTRW5ITVJ?
MONO-MAC-6	NETkfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTF6Nz6zPVIh\|ryP	NEXsOWVUSU6JRWK=
CAPAN-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTF6Nz60OVMh\|ryP	MoTJV2FPT0WU
SK-LU-1	NX;ZfIdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGD1c\|dKSzVyPUG4PE41OjhizszN	MYPTRW5ITVJ?
NCI-H1299	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTF6OD63NVkh\|ryP	MlvoV2FPT0WU
KG-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIWyZm1KSzVyPUG4PU44QThizszN	M{Hpc3NCVkeHUh?=
ETK-1	NEnl[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTF7MD6xPFEh\|ryP	M3S0O3NCVkeHUh?=
NCI-H838	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF7MD6zOEDPxE1?	NXzkdI44W0GQR1XS
HCE-4	M3P4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF7MD65PVIh\|ryP	M3HNZ3NCVkeHUh?=
A2780	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPpTWM2OD1zOUKuPFkyKM7:TR?=	MnjzV2FPT0WU
COLO-668	NV3yPYo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnwOWtSUUN3ME2xPVMvOTV5IN88US=>	M{KzWnNCVkeHUh?=
HGC-27	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTF7NT61N\|gh\|ryP	M4fUe3NCVkeHUh?=
SW1088	M4\kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3UfXFSUUN3ME2xPVUvPjd5IN88US=>	M4PocHNCVkeHUh?=
KOSC-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHBTWM2OD1zOUWuPFE5KM7:TR?=	NWS1NoFzW0GQR1XS
TE-1	NUPnbHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXpVVFKSzVyPUG5Ok4zPiEQvF2=	MleyV2FPT0WU
SW780	NVfGXIF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfIPZhyUUN3ME2xPVYvPzN2IN88US=>	NXvqZo5yW0GQR1XS
22RV1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfUTHk5UUN3ME2xPVcvPDJ2IN88US=>	NEHqTXNUSU6JRWK=
IA-LM	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni4TWM2OD1zOUeuPFIzKM7:TR?=	NV\vclNwW0GQR1XS
TE-5	NF3NTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT6e4hyUUN3ME2xPVgvODN\|IN88US=>	NHPM[lJUSU6JRWK=
JVM-3	M{\hVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTF7OD60NVkh\|ryP	NYThNGZIW0GQR1XS
HT55	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTF7OT6xPVIh\|ryP	MmHtV2FPT0WU
QIMR-WIL	NETKU\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3aTWM2OD1{MECuNVE3KM7:TR?=	NXj6Sph3W0GQR1XS
SJRH30	NEewUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPab\|BKSzVyPUKwNE42OTVizszN	NGK1[oFUSU6JRWK=
COLO-679	NV7VT3ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXESoF[UUN3ME2yNFAvQDV7IN88US=>	M1TMc3NCVkeHUh?=
MDA-MB-231	MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm0d3JOUUN3ME2yNFAvQTB{IN88US=>	NWHNeVl[W0GQR1XS
MFM-223	M{fSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJyMT61PFch\|ryP	MVTTRW5ITVJ?
MFE-280	MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTJyMT65OlEh\|ryP	MnGxV2FPT0WU
LAMA-84	NEDzW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PqO2lEPTB;MkCyMlA4OyEQvF2=	M3XtNHNCVkeHUh?=
LS-1034	NXn6PIxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPQZWtKSzVyPUKwNk42PTNizszN	NYHPZVZXW0GQR1XS
NCI-H345	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXuwfmNMUUN3ME2yNFMvODJ5IN88US=>	Ml;4V2FPT0WU
KYSE-70	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ixeGlEPTB;MkCzMlg4QSEQvF2=	NVjBU48yW0GQR1XS
EGI-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP6NINKSzVyPUKwOE45OzNizszN	MlzFV2FPT0WU
RPMI-2650	NXHQSYl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjLUFBKSzVyPUKwOU41PjdizszN	MWfTRW5ITVJ?
NCI-H1651	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTKRWtKSzVyPUKwOk44OyEQvF2=	MWnTRW5ITVJ?
HPAF-II	M4TX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHL4S2NKSzVyPUKwPU43PzFizszN	MVvTRW5ITVJ?
NUGC-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1v1SGlEPTB;MkC5MlY4QCEQvF2=	NEHHPIFUSU6JRWK=
DJM-1	Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYP0b203UUN3ME2yNFkvQDl5IN88US=>	NI\Ie49USU6JRWK=
MHH-PREB-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mli5TWM2OD1{MUCuN\|gyKM7:TR?=	M{HPOnNCVkeHUh?=
EW-18	NHHEOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfmOFNKSzVyPUKxNE44PjNizszN	Ml2xV2FPT0WU
BT-20	NILIVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD6TWM2OD1{MUCuPVg3KM7:TR?=	MYHTRW5ITVJ?
A431	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TnfmlEPTB;MkGxMlI6QSEQvF2=	NYnyWplTW0GQR1XS
TCCSUP	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\vTWM2OD1{MUGuOVM{KM7:TR?=	NVL0N3BMW0GQR1XS
HO-1-N-1	NFrwR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jENWlEPTB;MkGyMlg6PCEQvF2=	NXH2R4t[W0GQR1XS
NCI-H69	NXruZ5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmryTWM2OD1{MUSuNVg2KM7:TR?=	NIPmOWhUSU6JRWK=
ES7	NVrNUI12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4WzNWlEPTB;MkG0Mlg4QCEQvF2=	M1TnZXNCVkeHUh?=
C3A	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTJzNT61O\|Uh\|ryP	MkXWV2FPT0WU
UACC-257	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTJzNz60N{DPxE1?	NIq2TodUSU6JRWK=
DMS-153	M3zvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jqXGlEPTB;MkG3Mlg{PiEQvF2=	M370b3NCVkeHUh?=
LB771-HNC	NHP1Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDrS2lXUUN3ME2yNVcvQDl\|IN88US=>	NFr3PFJUSU6JRWK=
HOS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITJcWpKSzVyPUKxPE46KM7:TR?=	NIHtZZNUSU6JRWK=
THP-1	NEPFdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XyVGlEPTB;MkG5MlYxPiEQvF2=	NW\DUZI5W0GQR1XS
SCC-4	NEHKRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlT4TWM2OD1{MkCuN\|U{KM7:TR?=	MnjUV2FPT0WU
SCC-3	NGHOZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PuRWlEPTB;MkKwMlU4PyEQvF2=	MV3TRW5ITVJ?
BC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DlOGlEPTB;MkKwMlc6QSEQvF2=	MUTTRW5ITVJ?
NCI-H1618	M4DGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\SSWlEPTB;MkKxMlAyQCEQvF2=	NE\EVIhUSU6JRWK=
CaR-1	NUXQbldjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvRTWM2OD1{MkGuNlUyKM7:TR?=	NGfxeGFUSU6JRWK=
NCI-H1355	M3z6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XFdmlEPTB;MkKxMlM4PyEQvF2=	M2LRSHNCVkeHUh?=
NCI-H1993	NUXP[Y1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3[4b2lEPTB;MkKyMlI{QSEQvF2=	M4XaUXNCVkeHUh?=
NCI-H1623	NIn0VYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLIfnk5UUN3ME2yNlIvOzh7IN88US=>	NEjRSm5USU6JRWK=
AGS	NGLQXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrzeYpKSzVyPUKyNk42OjNizszN	MULTRW5ITVJ?
SAS	NYnmXJNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYC4VGRuUUN3ME2yNlMvPzl4IN88US=>	MV\TRW5ITVJ?
HCC1937	NIC1NGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LGfmlEPTB;MkK0MlM5QSEQvF2=	M1e5[nNCVkeHUh?=
NCI-H209	M4ruU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEG4b\|BKSzVyPUKyOk42OyEQvF2=	NWXmUJVPW0GQR1XS
NCI-H322M	MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPIfo5KSzVyPUKyPE4xOTlizszN	NGPaPZRUSU6JRWK=
CHL-1	NV\3NFZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfhWm1KSzVyPUKyPE4yOyEQvF2=	MUjTRW5ITVJ?
NCI-H630	NYTneJIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HnSmlEPTB;MkOyMlg6PyEQvF2=	MWPTRW5ITVJ?
5637	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLvVGxPUUN3ME2yN\|MvODB\|IN88US=>	MlXPV2FPT0WU
MSTO-211H	M4HzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ\|Mz6yO\|Yh\|ryP	M3:2UXNCVkeHUh?=
YAPC	NEPJUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3v6dmlEPTB;MkO0MlI2OyEQvF2=	MVPTRW5ITVJ?
SW1783	NVv5cJo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\nNZpKSzVyPUKzOE41OSEQvF2=	NVPlNmZGW0GQR1XS
GB-1	NYj2cFRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTFfpRVUUN3ME2yN\|UvOTd5IN88US=>	MnnCV2FPT0WU
NCI-H520	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJ\|NT63OFEh\|ryP	NH\zbW1USU6JRWK=
NOMO-1	M1WxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJ\|Nj6wNkDPxE1?	NVXLOYRUW0GQR1XS
NCCIT	NIDDbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jy[WlEPTB;MkO2Mlg4OyEQvF2=	MnLUV2FPT0WU
SW954	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPacI1KSzVyPUKzO{45PjhizszN	MU\TRW5ITVJ?
MOLT-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jhemlEPTB;MkSxMlIxQSEQvF2=	NHjUb2dUSU6JRWK=
EB2	NVfNR2ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIroT5VKSzVyPUK0NU46ODdizszN	MY\TRW5ITVJ?
IPC-298	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPSWGNnUUN3ME2yOFIvODd{IN88US=>	M1XzWHNCVkeHUh?=
GP5d	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7IXJI1UUN3ME2yOFIvPjF4IN88US=>	NGi1[5VUSU6JRWK=
HN	NFG2RmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjHTWM2OD1{NEKuPVkyKM7:TR?=	MYjTRW5ITVJ?
BFTC-909	NIjUTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLsWnl7UUN3ME2yOFMvOTF6IN88US=>	MWPTRW5ITVJ?
ES5	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DvdmlEPTB;MkS1MlA{QCEQvF2=	NGiycGhUSU6JRWK=
SK-HEP-1	M4nLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1L2SGlEPTB;MkS2MlA1OyEQvF2=	NEexVXdUSU6JRWK=
T47D	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfOTWM2OD1{NEeuNFE{KM7:TR?=	M4j6[3NCVkeHUh?=
KYSE-510	NWThUWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnXTWM2OD1{NEeuOVE4KM7:TR?=	NWfDPJo6W0GQR1XS
LC-1F	M1j5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2T6ZmlEPTB;MkS4MlE2PiEQvF2=	NGOyZ2ZUSU6JRWK=
NCI-H1693	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV30UmdTUUN3ME2yOFkvPDl3IN88US=>	M1jsUnNCVkeHUh?=
COR-L23	NVHMSHNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHQZVRGUUN3ME2yOVAvPDF{IN88US=>	NUHOe\|RLW0GQR1XS
NCI-H2228	M3HueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjVXolKSzVyPUK1NE45PjRizszN	NFjWNVFUSU6JRWK=
NCI-H460	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDVdYtKSzVyPUK1NU41OTdizszN	MlHXV2FPT0WU
TGBC1TKB	NEWySWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLZVppZUUN3ME2yOVIvQDd3IN88US=>	Mn7SV2FPT0WU
NCI-H1304	MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\TRWlEPTB;MkWzMlE2PiEQvF2=	MlzsV2FPT0WU
CAL-27	NVzafJBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTJ3Mz60PFUh\|ryP	Mn;mV2FPT0WU
NCI-H187	M4jTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInjN2FKSzVyPUK1Ok44PiEQvF2=	NWT3UW8{W0GQR1XS
HSC-2	M13SVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrSV2dKSzVyPUK1PE42QDRizszN	M1rFWnNCVkeHUh?=
CAL-39	Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjKTWM2OD1{NkCuNlczKM7:TR?=	NUP1TXFoW0GQR1XS
HuH-7	NWnS[mtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\KTWM2OD1{NkCuPVk3KM7:TR?=	M2P1WHNCVkeHUh?=
MMAC-SF	NX;lZopjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTZVo5mUUN3ME2yOlEvOTl{IN88US=>	NEjDd3hUSU6JRWK=
VA-ES-BJ	M2XXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTJ4MT65NVgh\|ryP	M2\TTnNCVkeHUh?=
A673	M2H6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ4Nz6wNlUh\|ryP	MkG3V2FPT0WU
LU-165	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2W0OWlEPTB;Mk[3Mlk1OSEQvF2=	NYPjT404W0GQR1XS
CAL-12T	M1njWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLyTWM2OD1{NkiuN\|Y3KM7:TR?=	MYTTRW5ITVJ?
RD	NYjQVm1QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTJ4OT6xNVkh\|ryP	MmP1V2FPT0WU
MDA-MB-468	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTWTWM2OD1{NkmuN\|M{KM7:TR?=	Mmf4V2FPT0WU
LN-405	NHXwR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrFfmtIUUN3ME2yOlkvPzB6IN88US=>	NYP6cGt{W0GQR1XS
MHH-CALL-2	NIDqT\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnoZ4ZRUUN3ME2yOlkvQTJizszN	NXTMfIIxW0GQR1XS
ES3	NHyzfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJ5MD6zOVgh\|ryP	NWXsNHpmW0GQR1XS
SK-MEL-3	NXnJ[2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJ5NT60OVch\|ryP	NWXDUW9UW0GQR1XS
TE-10	NWfuOphuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYC0XYlWUUN3ME2yO\|YvPDN7IN88US=>	M1TwS3NCVkeHUh?=
BEN	NHy4cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;MbGlEPTB;Mke2MlQ3OSEQvF2=	MYTTRW5ITVJ?
NB69	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrXTItKSzVyPUK3O{41ODVizszN	MX7TRW5ITVJ?
CAMA-1	NEm0ZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\kTHI5UUN3ME2yO\|gvOjd7IN88US=>	MXTTRW5ITVJ?
NCI-H1792	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljjTWM2OD1{N{muNVg4KM7:TR?=	M1[3NHNCVkeHUh?=
UACC-893	NVXQcoFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTJ6MD61OEDPxE1?	MnHmV2FPT0WU
TGW	M2DLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIP6ZZJKSzVyPUK4N{4xPThizszN	M3XPS3NCVkeHUh?=
SH-4	NXW1box3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGntTnVKSzVyPUK4N{4yOjNizszN	MlHYV2FPT0WU
NCI-H2009	NI\M[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTJ6Mz65OVMh\|ryP	MUTTRW5ITVJ?
T84	NETyR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTJ6ND62OlUh\|ryP	MYDTRW5ITVJ?
EW-7	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fz[GlEPTB;Mki1MlI{OiEQvF2=	MmHjV2FPT0WU
NCI-H1882	NFT0U\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHhVWt4UUN3ME2yPFYvODN3IN88US=>	NIixcFFUSU6JRWK=
GMS-10	NF7ldlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrQZZRKSzVyPUK4O{4yQDNizszN	M4HGW3NCVkeHUh?=
HC-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTnTWM2OD1{OUCuOlAzKM7:TR?=	MVvTRW5ITVJ?
ABC-1	M2Xw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlyzTWM2OD1{OUGuNFY6KM7:TR?=	NVTndXZ3W0GQR1XS
HuP-T3	M2G3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3i3W2lEPTB;MkmyMlE1PiEQvF2=	NYPKfnByW0GQR1XS
HT-1197	NFjxXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37WOmlEPTB;MkmyMlg4QSEQvF2=	NX;0[WRMW0GQR1XS
SHP-77	NHPLe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nUV2lEPTB;Mkm1MlU6PyEQvF2=	NXznTZc{W0GQR1XS
NCI-H524	NXvGVHlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jWV2lEPTB;Mkm1Mlc3QSEQvF2=	MoHhV2FPT0WU
SW626	NHvBco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTJ7Nj6xNVUh\|ryP	MU\TRW5ITVJ?
NCI-H2347	NWLQVJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPwZVlKSzVyPUK5Ok41OjVizszN	NVztOHl[W0GQR1XS
U251	NX[3TmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWD4dll[UUN3ME2yPVgvPDN6IN88US=>	MWDTRW5ITVJ?
RL95-2	M3rROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTNyMD6yOFch\|ryP	NGCwbVVUSU6JRWK=
C2BBe1	MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojWTWM2OD1\|MECuOlkyKM7:TR?=	MlGwV2FPT0WU
HLE	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDpOoYxUUN3ME2zNFEvQDF6IN88US=>	M1TUNHNCVkeHUh?=
COLO-680N	NIPJfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX4TWM2OD1\|MEKuPFk{KM7:TR?=	Mn[4V2FPT0WU
PLC-PRF-5	NE\CdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PMTmlEPTB;M{C0MlkxPyEQvF2=	MUPTRW5ITVJ?
SCC-15	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTNyNj6wNVch\|ryP	NV;ENZR7W0GQR1XS
ECC12	M3jIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTabHRwUUN3ME2zNVAvOjV2IN88US=>	MmnpV2FPT0WU
A388	NY\ZUG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfxcYtTUUN3ME2zNVIvODJ{IN88US=>	MkHEV2FPT0WU
ES1	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYn4RZJTUUN3ME2zNVIvOTh7IN88US=>	M1vNUnNCVkeHUh?=
J-RT3-T3-5	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnlTWM2OD1\|MUOuOVIyKM7:TR?=	MXLTRW5ITVJ?
SNU-475	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vFSGlEPTB;M{G0MlA6OSEQvF2=	NGrsc4JUSU6JRWK=
647-V	NUXwSmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\HO4xLUUN3ME2zNVQvPjd\|IN88US=>	MVHTRW5ITVJ?
IMR-5	NY\wT5pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTNzNT6zPEDPxE1?	MV3TRW5ITVJ?
EW-24	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTsXoJYUUN3ME2zNlAvODdizszN	MVXTRW5ITVJ?
CAL-51	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jIV2lEPTB;M{KxMlQxOyEQvF2=	MYDTRW5ITVJ?
HD-MY-Z	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETjVI9KSzVyPUOyNU41ODlizszN	MmrEV2FPT0WU
EW-13	NIK0OY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1W2WGlEPTB;M{KyMlQzPCEQvF2=	MlP0V2FPT0WU
SK-N-FI	M{XxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jzdWlEPTB;M{KyMlQ2OiEQvF2=	Mn34V2FPT0WU
BHY	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1mz[mlEPTB;M{KzMlE4PSEQvF2=	MkLRV2FPT0WU
OCUB-M	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nOcWlEPTB;M{KzMlQ{PCEQvF2=	MVLTRW5ITVJ?
HCC1954	M3LsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTN{Mz61PFIh\|ryP	M2X0[HNCVkeHUh?=
SK-MEL-24	NEG4TJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHsOoNKSzVyPUOyOE4yOTFizszN	MUjTRW5ITVJ?
NTERA-S-cl-D1	NED2OVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHGTWM2OD1\|Mk[uOFg6KM7:TR?=	Moq2V2FPT0WU
SK-MEL-30	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37vS2lEPTB;M{K2Mlc{QCEQvF2=	MYnTRW5ITVJ?
LS-123	NGj5dnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXaPHJCUUN3ME2zNlgvOTZ2IN88US=>	NH:wSFFUSU6JRWK=
SF268	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHkTIlKSzVyPUOzNE4zPjVizszN	MUjTRW5ITVJ?
BT-474	NVTodIZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\6ZWlEPTB;M{OyMlQyQCEQvF2=	NXPSdJY1W0GQR1XS
NCI-H1522	NGHyWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M336cmlEPTB;M{O0MlM{QSEQvF2=	NH\EblJUSU6JRWK=
LC-2-ad	NEO3WGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1[zW2lEPTB;M{O2MlU6OSEQvF2=	MkTiV2FPT0WU
LAN-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3SwSGlEPTB;M{O2Mlk4PyEQvF2=	NY\YU49oW0GQR1XS
ARH-77	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmW2TWM2OD1\|M{euN\|Ih\|ryP	M4OybnNCVkeHUh?=
HuO9	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPBfZlKSzVyPUOzO{41PyEQvF2=	MVjTRW5ITVJ?
MLMA	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vMUWlEPTB;M{O4MlE2PSEQvF2=	NF\rUXJUSU6JRWK=
Raji	M1TCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rT[WlEPTB;M{O4MlM5KM7:TR?=	NWTON2ViW0GQR1XS
GT3TKB	MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\rXmlEPTB;M{O4MlQyOiEQvF2=	NUHGboZ6W0GQR1XS
NCI-H441	NFjYOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTaWVltUUN3ME2zOFEvPDF6IN88US=>	M{W5c3NCVkeHUh?=
NCI-H2030	NXL5TGE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7jb5VKSzVyPUO0NU43ODlizszN	NGjySGhUSU6JRWK=
VM-CUB-1	NVzyempoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[4R3BbUUN3ME2zOFIvPjN4IN88US=>	NHHhdIxUSU6JRWK=
KP-4	NXG1RVNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLr[YZHUUN3ME2zOFMvPzN\|IN88US=>	NWTJNGpXW0GQR1XS
PF-382	M3zWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPOTVdKSzVyPUO0OE41OjJizszN	NIS3dYZUSU6JRWK=
NB13	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLoelJVUUN3ME2zOFUvPThizszN	M4fOTXNCVkeHUh?=
D-502MG	MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTNOIl2UUN3ME2zOFUvQDF{IN88US=>	Mlz2V2FPT0WU
CAL-54	NH;wOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTN2NT64O\|kh\|ryP	MkLrV2FPT0WU
DOHH-2	NX;QdWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTN2Nj62OUDPxE1?	NF7IW\|NUSU6JRWK=
SK-PN-DW	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfETWM2OD1\|NEeuOFI3KM7:TR?=	MWPTRW5ITVJ?
NCI-H720	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHixOVlKSzVyPUO0PU45PDZizszN	NFTQNm1USU6JRWK=
SW1990	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnDdYdKSzVyPUO1NU4zQCEQvF2=	M{HsOXNCVkeHUh?=
NCI-H2196	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4H3dGlEPTB;M{WyMlYzPCEQvF2=	NIDRSWRUSU6JRWK=
P30-OHK	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPQTWM2OD1\|NUOuNFY{KM7:TR?=	M1PzdHNCVkeHUh?=
NCI-H358	NV\zWXF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHWzZoRKSzVyPUO1OU4{PTZizszN	MoCwV2FPT0WU
CW-2	NUDrbJo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjXUmxKSzVyPUO1Ok42OjlizszN	NF3vemRUSU6JRWK=
COLO-678	M3Tyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLUc2xKSzVyPUO1O{45PjNizszN	NV;Ld5hsW0GQR1XS
NCI-H2126	M3nOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTN3OD61NlEh\|ryP	M{\vcnNCVkeHUh?=
DMS-53	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHYTWM2OD1\|NUiuO\|EyKM7:TR?=	M1XCcHNCVkeHUh?=
NCI-H1838	NFTY[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHHOHlKSzVyPUO1PU46QDdizszN	M{LJVHNCVkeHUh?=
SJSA-1	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjLeHZlUUN3ME2zOlAvQTN7IN88US=>	NUHZcIZYW0GQR1XS
ChaGo-K-1	M{DQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLKe244UUN3ME2zOlMvQTJ2IN88US=>	MX\TRW5ITVJ?
IST-SL2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXSbXdKSzVyPUO3Nk46OjZizszN	MorEV2FPT0WU
U-266	Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGryd2JKSzVyPUO3N{4yOzJizszN	NXz0UIFnW0GQR1XS
P31-FUJ	M4jT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUH5U3RVUUN3ME2zO\|YvQTZ2IN88US=>	MVPTRW5ITVJ?
HCC2157	M{ey[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTN5OD6xOlEh\|ryP	NH:wS3dUSU6JRWK=
COR-L88	NXHZZphJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTN6Mz62O\|ch\|ryP	MVHTRW5ITVJ?
NCI-H596	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTN6NT6zOEDPxE1?	NV3ydmF5W0GQR1XS
GOTO	NVLISpB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\qNmlEPTB;M{mwMlY1OSEQvF2=	Mn35V2FPT0WU
NCI-H719	M4[wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTN7MT64PVMh\|ryP	NWPYOI05W0GQR1XS
MN-60	NHrI[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvpTHY3UUN3ME2zPVMvQTR6IN88US=>	NG\sdIpUSU6JRWK=
IST-SL1	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXS1c4E{UUN3ME2zPVQvPDB4IN88US=>	MkniV2FPT0WU
TE-6	M3jvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfB[JNKSzVyPUO5O{4zPTRizszN	Ml3uV2FPT0WU
SW962	M{frPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTN7OD62PUDPxE1?	M{PEb3NCVkeHUh?=
FADU	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXoTWM2OD12MEOuNFg{KM7:TR?=	NXTZfWxZW0GQR1XS
ECC4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT1TWM2OD12MEiuOFU5KM7:TR?=	NXvTZVRVW0GQR1XS
MES-SA	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTRyOT65PEDPxE1?	MlvMV2FPT0WU
NCI-H716	NUXT[YlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\CbHVKSzVyPUSxNE4xPzVizszN	Mn3sV2FPT0WU
GR-ST	NIKxc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzCfoFKSzVyPUSxNE41QTdizszN	NFnyW3dUSU6JRWK=
KY821	M33qOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTRzND6wPFYh\|ryP	MVHTRW5ITVJ?
NCI-H2141	NUTkV\|hiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXGOWN3UUN3ME20NlQvOzh6IN88US=>	M2jIbHNCVkeHUh?=
MDA-MB-134-VI	NU\t[mNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjqbXpTUUN3ME20N\|EvODN\|IN88US=>	MW\TRW5ITVJ?
RH-1	NFX2SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED2[2RKSzVyPUSzOU4xQSEQvF2=	NHj6ZVFUSU6JRWK=
AM-38	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mki2TWM2OD12M{iuOVQh\|ryP	MWHTRW5ITVJ?
BL-70	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTR\|OT60Nlkh\|ryP	M2r5NXNCVkeHUh?=
COLO-684	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn0[JRnUUN3ME20OFgvQDh6IN88US=>	M4j3VHNCVkeHUh?=
DMS-79	NWG3eGo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TLdWlEPTB;NES5MlY5KM7:TR?=	MmDRV2FPT0WU
EW-1	NUfw[YZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NED3XYhKSzVyPUS1Nk45QDhizszN	NHu5UlBUSU6JRWK=
MS-1	NWHYXpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlr5TWM2OD12NUSuN\|g2KM7:TR?=	M1LzXXNCVkeHUh?=
A4-Fuk	NEDtUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnXbWY2UUN3ME20OVQvPTB5IN88US=>	MkLpV2FPT0WU
TALL-1	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\HZ2hKSzVyPUS1OU4zQTdizszN	M2rnXHNCVkeHUh?=
SCLC-21H	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moe4TWM2OD12NUWuOlk6KM7:TR?=	NYWzRopyW0GQR1XS
KMS-12-PE	M3jTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mof2TWM2OD12NU[uPFIzKM7:TR?=	MmSyV2FPT0WU
TE-441-T	NUfUc\|l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXz3OHZ1UUN3ME20OVcvOTh4IN88US=>	MYHTRW5ITVJ?
A3-KAW	NWDuflBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\B[JlKSzVyPUS2NE45PDFizszN	NWfPSndvW0GQR1XS
NCI-H1092	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;aTWM2OD12NkOuPVQ{KM7:TR?=	MV7TRW5ITVJ?
COR-L279	M{f1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPENmlKSzVyPUS2OE45PDdizszN	M4rWUnNCVkeHUh?=
NCI-SNU-5	NXHkR\|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTR5Mj6yPEDPxE1?	MXvTRW5ITVJ?
JAR	M4XCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfMTWM2OD12N{SuO\|g5KM7:TR?=	MV;TRW5ITVJ?
NCI-H446	NFn1[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTR5Nz6wPEDPxE1?	NEL6c\|JUSU6JRWK=
HDLM-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P4WWlEPTB;NEiwMlg3QSEQvF2=	MonRV2FPT0WU
D-283MED	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Hhe2lEPTB;NEi4MlkzPCEQvF2=	NUXnSIV[W0GQR1XS
NCI-H1395	NFHlTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU[wZlVWUUN3ME20PFkvODB2IN88US=>	NF3WS5pUSU6JRWK=
RPMI-6666	NV:4VGtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\sXmlEPTB;NEmxMlM6QCEQvF2=	MX\TRW5ITVJ?
CPC-N	NXTv[GY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTVyMj6wOlMh\|ryP	Mo[xV2FPT0WU
EC-GI-10	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\6TWM2OD13MEKuNVY6KM7:TR?=	MWnTRW5ITVJ?
CA46	M1\qcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHmTWM2OD13MESuOFA4KM7:TR?=	M3nyfnNCVkeHUh?=
EHEB	NHPkZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTVyNz6yNFgh\|ryP	NYXyc5dpW0GQR1XS
RPMI-8402	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;lTWM2OD13MUCuNFIyKM7:TR?=	M1Hoe3NCVkeHUh?=
DU-4475	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTVzMT6xNFEh\|ryP	M17k[nNCVkeHUh?=
P12-ICHIKAWA	M1jG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDsTWM2OD13MUGuOFE3KM7:TR?=	M4nmcXNCVkeHUh?=
NCI-H1694	M1z1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPqVIJJUUN3ME21NVIvPDN7IN88US=>	NYfRS\|NbW0GQR1XS
NCI-H2171	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXoXFhKSzVyPUWxNk44ODVizszN	NWr2ZYZGW0GQR1XS
Mo-T	M1v6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\LTWM2OD13MUWuNVE3KM7:TR?=	M2jhUnNCVkeHUh?=
HL-60	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\CTWM2OD13MkKuPVI1KM7:TR?=	M1uyV3NCVkeHUh?=
NCI-H1436	NELOOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DvU2lEPTB;NUKzMlA3PCEQvF2=	M2e3N3NCVkeHUh?=
NCI-H510A	NIXC[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTV{ND62PVYh\|ryP	MVjTRW5ITVJ?
NCI-H2081	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljuTWM2OD13MkWuOVE{KM7:TR?=	MVTTRW5ITVJ?
NB5	MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfuTYFKSzVyPUWyOk41OyEQvF2=	MWfTRW5ITVJ?
NCI-H2227	NE\LOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTV\|MD6yOVQh\|ryP	NXzDXFNMW0GQR1XS
HSC-4	NV\6SGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\kdWlEPTB;NUO5MlI6OyEQvF2=	NGS5c45USU6JRWK=
RL	NGDaO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjo[2w1UUN3ME21OFIvPDR{IN88US=>	MUPTRW5ITVJ?
EVSA-T	MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfFTWM2OD13NEOuOlg1KM7:TR?=	M4LLOnNCVkeHUh?=
NCI-H889	M3;Ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTV2Nz6yN{DPxE1?	M3n0N3NCVkeHUh?=
COLO-320-HSR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHFTWM2OD13NUGuN\|Uh\|ryP	MlPjV2FPT0WU
EW-11	NWrqOGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LPb2lEPTB;NUWyMlM6QSEQvF2=	MXHTRW5ITVJ?
UACC-812	NYfufHVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3OTWM2OD13NUmuN\|kyKM7:TR?=	NGDG[mFUSU6JRWK=
CAL-148	NXTTPGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LqUWlEPTB;NU[1MlA5QSEQvF2=	NFK0VIhUSU6JRWK=
K052	NFXITJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\NOWlEPTB;NUe5MlIyOyEQvF2=	M1\WS3NCVkeHUh?=
L-428	MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHWz[JFKSzVyPU[wNE43PzFizszN	M3jmfXNCVkeHUh?=
LP-1	M{ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzzcGcxUUN3ME22NFMvPTh5IN88US=>	M125dXNCVkeHUh?=
ML-2	NGnSSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHRXoFWUUN3ME22NFYvPTd7IN88US=>	NXeyRnNMW0GQR1XS
KARPAS-45	NXfKN4JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PqRWlEPTB;NkG4MlIzOSEQvF2=	NFT2O2FUSU6JRWK=
HT	NELGNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXiTWM2OD14MkKuO\|g2KM7:TR?=	NHrTco9USU6JRWK=
NCI-H226	NHzUTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfmUY9KSzVyPU[yPE4{PTNizszN	MV7TRW5ITVJ?
L-363	NGnqN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTZ2OD6wOlQh\|ryP	MlS1V2FPT0WU
IM-9	NVTueZFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\R[WlEPTB;NkWxMlU1OSEQvF2=	NXPaTpRYW0GQR1XS
TUR	NWfUVFZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvOTWM2OD14N{GuN\|IzKM7:TR?=	MV\TRW5ITVJ?
NCI-SNU-16	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrKdlBmUUN3ME22PFAvPDZ{IN88US=>	MmOzV2FPT0WU
NCI-SNU-1	NYjkTlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTZ7MD6xO\|Ih\|ryP	NGjSS\|JUSU6JRWK=
U-87-MG	M3XNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTZ7ND61PFUh\|ryP	M2XnOHNCVkeHUh?=
KM-H2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHe5WmhKSzVyPU[5PU4xPTlizszN	M1XsN3NCVkeHUh?=
DEL	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnyPXBKSzVyPUewNE45OzhizszN	M1Hyb3NCVkeHUh?=
KARPAS-422	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\qfnlDUUN3ME23PFkvOzF3IN88US=>	NU\CN2FzW0GQR1XS
BC-3	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRThyNT6yNFMh\|ryP	MV\TRW5ITVJ?
NCI-H1155	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2THdWlEPTB;OEG4MlA2QSEQvF2=	NYXUfVVFW0GQR1XS
NCI-H1581	NH;Gc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\5c3dKUUN3ME25NFAvOjNzIN88US=>	MlXvV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / CD31 / VE-Cadherin / α-SMA / vimentin; PubMed: 30709379 J Exp Clin Cancer Res NCI-H460 cells were co-cultured with HUVECs in a 3D culture system, and then treated with 1 μM CHIR-99021, 10 μM or 20 μM Cisplatin, or a combination of both, for 24 h. Cells were harvested and immunoblotted with anti-cleaved PARP, anti-CD31, anti-VE-cadherin, anti-α-SMA, anti-vimentin, and anti-β-actin antibodies. CTNNB1; PubMed: 23993102 Cell Treatment with the GSK3β inhibitor CHIR-99021 led to increased levels of β-catenin in RKO and HT29 (non-mutant) cells. β-catenin; PubMed: 24165128 J Biol Chem HeLa cells were treated with 5 μm CHIR-99021 for the indicated times. The samples were analyzed by Western blot.	30709379 23993102 24165128
Growth inhibition assay	Cell viability; PubMed: 22039301 J Immunol HMC-1.2 cells were cultured in the absence or presence of GSK3β inhibitor (CHIR 99021, 3–30 µM) and viability cell count was assessed by trypan blue dye exclusion after 24 h, 48 h or 72 h. All data are presented as the mean ± SEM of three independent experiments conducted in triplicate. p < 0.05, p < 0.001* p < 0.0001*** vs vehicle treated control cells.	22039301
Immunofluorescence	SOX10 / EdU; PubMed: 28174705 Cell Mol Gastroenterol Hepatol Incorporation of EdU (white arrowheads) into SOX10+ ENS (enteric nervous system) cells with and without CHIR-99021. Oct3/4; PubMed: 24779365 BMC Res Notes Fluorescence micrographs showing the protein expression of Brachyury/Oct3/4 after a three day differentiation of ES-D3 cells with BIO (0.5 μM), SB-216763 (5 μM), CHIR-99021 (5 μM), or CHIR-98014 (1 μM). Nuclei were counterstained with DAPI (blue). The merge is shown in yellow. Original magnification 400x. Scale bar = 50 μm.	28174705 24779365

In vivo

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge. ^[1] Administration of CHIR-99021 significantly augments hematopoietic repopulation in recipient mice transplanted with mouse or human hematopoietic stem cells (HSCs), suggesting that GSK-3 is a specific modulator of HSC activity. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Cell-free kinase assays: Polypropylene 96-well plates are filled with 300 μL/well buffer (50 mM tris HCl, 10 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, 0.01% BSA, pH 7.5) containing 27 nM GSK-3α or 29 nM GSK-3β, and 0.5 μM biotin-CREB peptide substrate. Various concentrations of CHIR-99021 are added in 3.5 μL of DMSO, followed by 50 μL of ATP stock to yield a final concentration of 1 μM ATP in all cell-free assays. After incubation, triplicate 100-μL aliquots are transferred to Combiplate eight plates containing 100 μL/well 50 μM ATP and 20 mM EDTA. After 1 hour, the wells are rinsed five times with PBS, filled with 200 μL of scintillation fluid, sealed, left 30 minutes, and counted in a scintillation counter. All steps are performed at room temperature.
Cell Research: ^[3]	- Collapse Cell lines: INS-1E Concentrations: Dissolved in DMSO, final concentrations ~ 20 μM Incubation Time: 1, or 4 days Method: Cells are maintained for 24 hours in starvation medium (culture medium with only 5 mM glucose, 1% fetal calf serum). Then cells are exposed to various concentrations of CHIR-99021 for 1, or 4 days. Cell number is measured by staining of cellular DNA with CyQuant dye, which becomes fluorescent when bound to DNA. Fluorescence is measured after 30 minutes of incubation using the FLUOstar Optima reader. Cell replication is determined by BrdUrd incorporation. BrdUrd labeling solution is added to the medium for the last 4 hours before the cells are fixed using FixDenat solution and incubated with monoclonal anti-BrdUrd-POD antibodies. After substrate solution is added to each well, the light emission is measured in a microplate luminometer using the Analyst HT detection system. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female db/db mice or male ZDF rats with type 2 diabetes Dosages: ~48 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL (185.33 mM)
	Ethanol	2 mg/mL (3.98 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	24mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Molecular Weight	501.8
Formula	C₂₂H₁₈Cl₂N_8.HCl
CAS No.	1797989-42-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	Cl.CC1=C[NH]C(=N1)C2=CN=C(NCCNC3=NC=C(C=C3)C#N)N=C2C4=CC=C(Cl)C=C4Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I recently purchased CHIR 99021 to inject mice intraperitoneally. The data sheet says using 10% captisol for in vivo use. Is it for IP injection? Or do you have other solutions to suggest to use for in vivo IP injection of CHIR 99021?
Answer:
The formulation of 15% Captisol is for oral gavage, and S2924 CHIR-99021 (CT99021) HCl in it is a suspension. S2924 CHIR-99021 (CT99021) HCl can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 24mg/ml as a clear solution for IP injection.
Question 2:
How about the half-life of this compound? If it is necessary for daily treatment when the compound is used in long-term experiment?
Answer:
Please change the culture medium each day to add the new comound in it if the duration is more than 72h.
Question 3:
What is the difference between S2924 and S1263? Which one is better for differentiation?
Answer:
S1263 is the free base format of Chir-99021, while S2924 is the HCl salt format. They have the same biological activity but are slightly different in solubility.

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Selective GSK-3 Inhibitor

TWS119 : GSK-3β-selective, IC50 of 30 nM.
Most Potent GSK-3 Inhibitor

CHIR-98014 : GSK-3α, IC50=0.65 nM; GSK-3β, IC50=0.58 nM.
GSK-3 Inhibitor in Clinical Trial

Tideglusib : Phase II for Alzheimer's disease.
Newest GSK-3 Inhibitor

AZD1080 : Orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with K_i of 6.9 nM and 31 nM, respectively.

Related GSK-3 Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
LY2090314 ^New

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
TDZD-8 ^New

TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
TWS119

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology.
SB216763

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β.
Tideglusib

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
CHIR-98014

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
BIO

BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.

Features:The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
AR-A014418

AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and K_i of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.
IM-12

IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl